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Abstract 
 The effects of an anthocyanin-rich black elderberry extract (BEE) on cardiovascular 
disease (CVD) risk and obesity-induced metabolic dysregulation were tested inApoE-/- mice and 
C57BL/6J mice, respectively.  ApoE-/- mice were fed either a low fat AIN-93Mdiet 
supplemented with 1.25% (wt/wt) BEE or control diet (LFD) to male apoE-/- mice for 6 weeks. 
The anthocyanin-rich BEE fed to mice was rich in cyanidin 3-sambubioside (~9.8% wt/wt) and 
cyanidin 3-glucoside (~3.8% wt/wt). After 6 weeks, serum lipids did not differ significantly 
between groups, while aspartate transaminase (AST) and fasting glucose were reduced in BEE-
fed mice. Hepatic and intestinal mRNA changes with BEE-feeding were consistent with an 
improvement in HDL function (Apoa1, Pon1, Saa1, Lcat, Clu) and a reduction in hepatic 
cholesterol levels (increased Ldlr and Hmgcr, reduced Cyp7a1). In BEE-fed mice, serum 
paraoxonase-1 (PON1) arylesterase activity was significantly higher.  In addition, mice fed BEE 
had significantly lower serum monocyte chemoattractant protein-1 (MCP-1) and tended to have 
lower serum thiobarbituric acid reactive substance (TBARS) (p = 0.09) compared to control-fed 
mice. Notably, we observed significant reductions in cholesterol content of the aorta of BEE-fed 
mice, indicating less atherosclerosis progression. This study demonstrates that black elderberry 
may serve as a useful dietary component to prevent HDL dysfunction associated with chronic 
inflammation.  
The objective of the second study was to determine if BEE could protect against low-
grade chronic inflammation and insulin resistance in a high fat diet-induced obesity model using 
C57BL/6J mice.   Mice were either fed a low fat diet (LFD), high fat diet (HFD), HFD + 0.25% 
(w/w) BEE (0.25% BEE), or HFD + 1.25% BEE (1.25% BEE) for 16 weeks.  The 0.25% BEE 
and 1.25% BEE diets corresponded to 0.04% anthocyanin (w/w) and 0.20% anthocyanin (w/w) 
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in diets, respectively. After 16 weeks, there were significant reductions in liver weight, fasting 
TG, fasting insulin, MCP-1, and serum tumor necrosis factor alpha (TNFα) in BEE-fed mice 
compared to the HFD control. Liver cholesterol was significantly lower in 1.25% BEE compared 
to the other HFD groups. The homeostatic model assessment method (HOMA) values were 
significantly lower in the BEE-fed groups, indicating higher insulin sensitivity. Hepatic fatty acid 
synthase (FAS) mRNA was lower in the BEE-fed groups and peroxisome proliferator-activated 
receptor gamma 2 (PPARg2) mRNA was reduced in 1.25% BEE suggesting decreased 
lipogenesis in BEE-fed mice. Gene expression analysis indicated a pro-fibrogenic phenotype in 
the adipose tissue of the 1.25% BEE group.  These results suggest that BEE may have potential 
as a functional food to help reduce the risk of inflammation and insulin resistance in obesity. 
However, research in humans is warranted. 
 
Introduction 
 In 2012, about 38 million people died from noncommunicable, preventable chronic 
diseases such as obesity, diabetes, cancer, heart disease, etc(1).  In the same year, 17.5 million 
people died from cardiovascular disease (CVD(1).  Of that 17.5 million people, 7.4 million 
people died from coronary heart disease(1), also known as ischemic heart disease or 
atherosclerotic heart disease, which is one of the largest contributors to CVD deaths and of 
particular interest.  Additionally, millions die each as a result of obesity-related 
complications(2).Despite increased information about healthy dietary habits, these two killers 
remain major concerns and continue to increase in prevalence.  Chronic low-grade inflammation 
has been implicated in many noncommunicable diseases including heart disease and obesity(3).  
Lowering inflammation may, therefore, be an effective way of reducing both the risk of 
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developing and dying from such diseases. For example, obesity itself does not kill people 
directly, it kills by causing a variety of obesity-related comorbidities(4), such as CVD, diabetes, 
and certain cancers, and obesity may accomplish this by causing excess inflammation. 
 Atherosclerotic heart disease risk is often assessed clinically via typical blood lipids such 
as total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein 
cholesterol (HDL-C), and triglycerides.  However, therapies to improve these markers have 
either been ineffective at reducing disease risk or leave significant residual risk suggesting that 
these markers have a correlational but not a causational relationship with the disease(5, 6).  This 
warrants restructuring of the HDL hypothesis, which states that HDL-C is protective against 
CVD.  Focus has now shifted towards HDL function, assessing markers such as the lipoprotein’s 
ability to efflux cholesterol, act as an anti-inflammatory agent and powerful antioxidant, improve 
immune function, reduce clotting, etc.  Inflammation can contribute to the etiology of CVD in 
several ways, one of which includes interfering with proper HDL function(7).  Inflammation can 
promote a pro-inflammatory HDL particle as well as the progression of atherosclerosis(8).   
 The excess lipid accumulation in obesity results in an increase circulating non-esterified 
free fatty acids (NEFA) when the adipocytes become overloaded with lipid.  This NEFA 
circulates and can become incorporated into triglycerides and deposited into tissues such as the 
liver, pancreas, kidney, heart, etc.  This is good to some degree because NEFA is more harmful 
circulating in the blood but these tissues do not have a high capacity to store lipid and when the 
liver, for example, become overloaded with lipid, the lipid can become toxic and cause tissue 
damage and inflammation such as steatohepatitis and eventually liver cirrhosis in this case.  In 
this way the lipid overload that occurs in obesity contributes to inflammation in the adiposetissue 
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and systemically(9).  It is this inflammation that likely leads to many of the obesity-related 
comorbidities(10, 11). 
 Diet is one possible means of reducing inflammation.  Fruits and vegetables are thought 
to reduce the risk of many diseases (12, 13) including CVD and obesity, and inflammation may 
be responsible for some of this effect.  Vitamins and minerals present in fruits and vegetables 
may be one way inflammation is lowered but there are many other compounds in these plants.  
Dietary bioactives include these nonessential molecules in fruits and vegetables that may be 
beneficial to health(14).  Polyphenols are one class of dietary bioactives that are have received a 
lot of attention in scientific research.  Anthocyanins are one class of polyphenols and are of 
particular interest.  Anthocyanins are a class of polyphenols that have been shown to be anti-
inflammatory(15).  Anthocyanins have been shown to improve HDL function and reduce 
atherosclerosis(16, 17).  They have also been shown to reduce weight gain and improve insulin 
sensitivity in obese-related studies(18, 19).  The absorption of anthocyanins in their intact form is 
very low (20)and some have questioned whether their systemic effects are merely a product of 
their effects at the intestine.However, it is now known that anthocyanins make it to the blood in 
the form of metabolites (21). Anthocyanins may, therefore, prove to be useful in the treatment or 
prevention of cardiovascular disease and obesity.  However, people do not eat purified 
anthocyanins and there are many sources in nature.  One source of anthocyanins that are of 
interest is berries. 
 Black elderberry, which has been used medicinally in European and Native American 
cultures for thousands of years(22, 23), is one of the highest berry-derived sources of 
anthocyanins(19, 24).  Often used in times of sickness, black elderberry may have helped treat 
conditions like the common cold, respiratory infections, and fever at least partially by reducing 
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inflammation.  The European variety (SambucusNigra) is more readily known for its use in 
traditional medicine; however, research on the berry is very limited.  For this reason, we asked 
two questions regarding its potential therapeutic effect on inflammation in CVD and obesity.   
 Consequently, for our first aim we asked whether a black elderberry extract (BEE) can 
reduce inflammation and therefore CVD risk in ApoEknockout (KO,-/-) mice (mouse modelwith 
highsusceptibility to atherosclerosis) when fed in the diet.  Since inflammation can contribute to 
the etiology of CVD by both interfering with HDL function and progressing atherosclerosis, 
reducing inflammation may improve HDL function and decrease atherosclerosis.We therefore 
hypothesized that a BEE supplemented diet would reduce inflammation in ApoE -/- mice and 
thereby improve HDL function and reduce atherosclerosis.   
 For our second aim, we asked whether BEE-feeding could reduce inflammation and 
consequently ameliorate the metabolic dysfunction of obesity in C57BL/6J mice (mouse model 
prone to obesity and diabetes).   Reducing inflammation may reduce tissue damage and 
subsequent metabolic dysfunction both directly, by lowering inflammatory signaling in those 
tissues, and indirectly, by lowering the concentrations of circulating NEFA through decreasing 
lipolysis and promoting storage into triglyceride and adipose tissue.  An example might include 
preventing the development of steatosis into steatohepatitis. Thus, our hypothesis for this aim 
was that a BEE-supplementation would reduce inflammatory factors, insulin resistance, adipose 
leukocyte infiltration and blood lipids in C57BL/6J mice.   
It is our hope that data generated from these studies will provide valuable information as 
to whether BEE may or may not be of benefit in preventing the development of chronic 
inflammatory diseases. 
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Chapter 1: Review of Literature 
EPIDEMIOLOGY OF CHRONIC DISEASE 
It is estimated thatthere were 56 million deaths worldwide in 2012(1).  It is also estimated 
that about 68% of those deaths were caused by noncommunicable diseases (NCDs), or chronic 
diseases (1). The number one killer is thought to be cardiovascular disease (CVD), causing an 
estimated 17.5 million deaths in 2012, about one third of total deaths(1).  About 7.4 million of 
those deaths come from ischemic heart disease(1).   
Unlike cardiovascular disease, obesity, another major concern worldwide, does not 
appear on the Center of Disease Control’s (CDC) list of leading causes of death(25).  This seems 
puzzling because we know obesity is a sign of ill health and has a prevalence rate that is 
comparable to CVD. About 66.2% of U.S. adults 20–74 years old were estimated to be either 
overweight or obese in 2003-2004 according to the National Health and Nutrition Examination 
Survey (NHANES) data (26).The global rate of overweight and obese individuals was estimated 
to be approximately 35% of the world population, ages 20 and over, as over 2008(2).While not 
as high as the U.S. rate it is still very concerning.  The world organization of health organization 
(WHO) estimates that at least 2.8 million people die each year as a result of being overweight or 
obese(2).  The WHO makes such a significant estimate, yet the CDC does not list obesity as a 
leading cause of death in a country that has one of the highest prevalence rates.  This is because 
people don’t truly die from obesity, they die from complications caused by obesity that manifest 
themselves as cardiovascular disease, diabetes, certain forms of cancer and more.  These are 
known as obesity-related comorbidities.  These comorbidities are thought to be a result low-
grade chronic inflammation that occurs in obesity(4).  In fact, alterations in normal inflammatory 
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processes have been implicated in many different disease states(27).  Targeting inflammation 
may be an effective approach to treating both CVD and obesity.   
INFLAMMATION 
Inflammation is a very complex, bodily process in response to cellular injury.  The injury 
can be the result of many different things including microbial pathogens, allergens, or any other 
source of cellular damage.  It is thought that inflammation serves to aid in the clearance of any 
existing pathogen and in the healing of the tissue.  On the macroscopic scale it is characterized 
by the symptoms heat, redness, swelling, pain and loss of function.  On a microscopic scale it is 
characterized by the recruitment of immune cells, the increased permeabilityand dilation of 
blood vessels, and the production of molecular mediators, which can act to either propagate or 
resolve the inflammatory response.  
Classic inflammation (A.K.A. acute inflammation or “hot inflammation”) is characterized 
by a strong response to a stimulus or pathogen followed by proper resolution and healing.  
Inflammation begins with the recognition of pathogen-associated molecular patterns (PAMPs) by 
receptors on the surface of resident immune cells, typically macrophages(28).  The resident cells 
then secrete a cocktail of inflammatory mediators, which act to propagate the signal, recruit other 
immune cells, and increase vascular permeability(29).  For example, resident macrophages can 
secrete things like monocyte chemoattractant protein 1 (MCP1), to recruit other leukocytes to the 
area(29).  Upon removal of the pathogen, signaling shifts to support resolution.  Macrophages 
and other immune cells can undergo a phenotypic switch in which their role changes from an 
inflammatory one to an anti- or non-inflammatory, fibrotic, reparative one(30).  With the 
pathogen removed and the tissue healed, the system returns to homeostasis.  This kind of 
inflammation is characterized by an increase in energy expenditure and insulin resistance(31).  
This is what happens in health but in disease it is a different story.   
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In disease, the inflammatory process is not properly resolved.  This may result from an 
ongoing stimulus, such as a chronic infection, or because of faulty resolution(32).  In either case, 
the inflammatory process will not be entirely shut off, hence, a low-grade chronic inflammation 
(A.K.A. metaflammation or “cold inflammation”).  Although, this type of inflammation is also 
characterized by insulin resistance, contrary to acute inflammation, chronic inflammation is 
accompanied with a decrease in energy expenditure(31).  This leads to excessive tissue damage 
and can perpetuate the cycle of ill health. 
Chronic low-grade inflammation has been implicated in many different disease 
states(27).  It is thought that a malfunctioning in the proper resolution of inflammation or 
continuous stress that causes this chronic inflammation be at least one contributing factor in the 
etiology of chronic diseases(33).  If this is true, restoring proper resolution or lowering 
inflammation may be one effective way of treating or preventing many diseases.  There are 
several ways to go about lowering inflammation including drugs, diet, and lifestyle intervention. 
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FIGURE 1.2.1.  Chronic Inflammation in Disease 
 
 
OBESITY  
 Obesity is a condition involving the excess accumulation of body fat. Numerically it is 
defined as any individual with a body mass index (BMI) over 30kg/m2(34).  This excess fat 
accumulation is associated with a host of other problems and obese individuals are thought to be 
at an increased risk for a number of complications including insulin resistance and diabetes, 
cardiovascular disease, and many cancers including breast, colon, kidney, pancreatic, and thyroid 
cancer (35).   
 The fat accumulation that occurs in obesity is not necessarily dangerous.  Some studies 
have revealed a metabolically healthy obese phenotype (36).  The problem is thought to come 
when there is inflammation originating from the adipose tissue or when there is an excess of 
peripherally circulating and stored fatty acid(9).  The proportions of specific fatty acids stored 
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could be one difference that might explain why two individuals with similar BMIs, or amounts of 
adipose tissue, may have great variance in the inflammatory states of their respective adipose 
depots.  Saturated fats, for instance, are classically ridiculed because when circulating in the free 
form, they may activate inflammatory pathways by binding to toll-like receptor 4 (TLR4)(37).  
On the other hand, excess accumulation of polyunsaturated fatty acids may also play a role in 
modulating the inflammatory balance of the adipose tissue(38).  Both omega-6 and omega-3 
polyunsaturated fatty acids are enzymatically oxidized into many different molecular mediators 
of inflammation, collectively called eicosanoids.  Enzymatic breakdown of omega-3 fatty acids 
produces much less inflammatory eicosanoids than does the enzymatic breakdown of omega-6 
fatty acids, which is why omega-3s are often purported to be healthy.  However, both omega-3 
and omega-6 fatty acids are quite prone to non-enzymatic oxidation with omega-3s being the 
most susceptible.  This “peroxidation” contributes to the formation of reactive oxygen species 
(ROS), which are known activators of inflammatory processes(39).  With many factors to 
consider, the inflammatory environment is undeniably complex but fatty acids are clearly one 
piece of the puzzle.  
 Levels of peripherally circulating fatty acids, or non-esterified free fatty acids (NEFA) 
are elevated when there is in increase in lipolysis.  One reason lipolysis may be elevated is if 
there is an increase in adipose tissue turnover.   Greenberg et al. describe that rates of lipolysis 
are often higher in obese individuals(40).  This is partially because adipocytes are surrounded an 
extracellular matrix which includes collagen.  When the adipocytes need to expand to store more 
lipid, the collagen surrounding must first be broken down to allow for expansion.  This 
breakdown is mediated by matrix metalloproteinases (MMPs), however, Denis et al. describe 
that in obesity, collagen deposition and turnover is often dysfunctional resulting in adipose that is 
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unable to expand(41).  This is thought to be a leading cause of excess circulating NEFA.  This 
excess collagen deposition or fibrosis is characterized by increase in collagen VI.  White adipose 
tissue (WAT) collagen VIis associated with insulin resistance and inflammation(42).  Several 
studies attempting to alleviate this fibrotic phenotype using genetic knockout (KO) mice have 
been shown to allow for increased adiposity, yet increased glucose control with lower plasma 
lipid suggesting a more metabolically healthy obese mouse.  Collagen VI KO mice, for example, 
had more hypertrophic adipocytes, more total adipose mass, greater glucose tolerance, lower 
fasting insulin and lower serum triglyceride than control ob/ob mice (43).  
In the healthy or lean state the adipose tissue is characterized by normal sized adipocytes, 
a low level of lipolysis and NEFA, high levels of adiponectin, and non-inflammatory immune 
cells, such as macrophages of the M2 phenotype, secreting anti-inflammatory cytokines 
including interleukin 4 (IL4), interleukin 10 (IL10), and interleukin 13 (IL13)(44).  In an obese, 
inflammatory state, however, adipocytes become hypertrophic with increased lipolysis, lower 
levels of adiponectin, and inflammatory immune cells, such as the pro-inflammatory M1 
macrophage, which secrete inflammatory cytokines/adipokines including TNFα, interleukin 6 
(IL6), interferon gamma (IFNγ), and interleukin 1 beta (IL1β)(44).  Lipid-overloaded 
inflammatory adipocytes become more lipolytic, which increases circulating NEFA.  Circulating 
NEFA interfere with proper glucose metabolism and are thus harmful to the organism(45).  In an 
attempt mitigate the toxic effects of circulating NEFA, the body will store these fatty acids as 
triglyceride in other tissues including the liver, pancreas, skeletal muscle, etc.  Although, the 
fatty acids are safer stored in such a way, they can still be harmful in this form.  Tissues other 
than the adipose are not designed for the storage of lipid and so the excess lipid accumulation in 
cells is quite toxic.  Since lipotoxicity in obesity results in the engorgement of lipid in certain 
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organs this may explain obesity’s ability to increase proclivity towards cancers in certain tissues 
known to be prone becoming fatty, such as the kidney or pancreas(9).    
FIGURE 1.3.1.  Inflammation in Obesity 
 
 
CARDIOVASCULAR DISEASE 
 Cardiovascular disease consists of many different disease that affect the heart and blood 
vessels.   Ischemic heart disease (IHD), also known as coronary heart disease or atherosclerotic 
heart disease, with over 40% of all CVD deaths is one of major contributors(1).  It has been 
estimated that 90% of CVD is preventable through means of our environment, such as diet and 
lifestyle factors(46).  If this is true, then figuring out what exactly lifestyle habits should be in 
order to reduce risk by this degree is much more complex.  Even statins are estimated to reduce 
risk of mortality by only22-25% in those with preexisting heart disease and by 12% in those 
without preexisting heart disease(47-49). Other studies have even shown no reduction in all-
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cause mortality in high-risk primary prevention (50).  There is likely plenty of residual risk to 
target even for those on statins. Understanding the etiology of atherosclerosis is essential to 
speculating what may help prevent it.   
 Atherosclerosis is most often correlated with dyslipidemia and high cholesterol.  From 
the famous Framingham Heart Study we know that low-density lipoprotein (LDL) (“bad 
cholesterol”) is positively associated with heart disease, whereas high-density lipoprotein (HDL) 
(“good cholesterol”) is negatively associated with heart disease(51).  These associations have 
been shown to be quite complex, however, and not a definite prediction of risk in all individual 
cases.There are many things that predispose someone to an increased risk for developing CVD.  
While risk factors like family history and ethnicity cannot be changed, things like high 
cholesterol, hypertension, obesity, sedentary behavior, insulin resistance, smoking, and diet may 
be controlled to some degree.  Many of these risk factors may be contributing to risk by 
promoting inflammation. 
 Inflammation and oxidative stress are key to the development of atherosclerosis(52).  
LDL particles first must penetrate the endothelial wall and become oxidized for the disease 
process to begin.  Intact LDL particles do not appear to be inflammatory since it is primarily 
oxidized LDL (oxLDL) that recruits macrophages to the vessel wall(53).  The macrophages 
engulf the oxLDL and become lipid-laden foam cells.  These foam cells are what primarily make 
up fatty streaks, or the first sign of atherosclerosis on the endothelial wall that is visible to the 
naked eye.  Eventually if the oxLDL burden continues the foams cells can become so engorged 
with the toxic lipid that they will die.  The necrotic foam cells create more inflammation and 
damage the surrounding tissue.  If the stress continues, collagen and dividing smooth muscle 
cells will act to fix the endothelial wall and to contain the inflammatory core of lipid by forming 
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a fibrous cap.  As the lipid core expands it may, at some point, burst the fibrous cap releasing its 
contents into the lumen of the blood vessel.  This will cause the activation of platelets and quick 
coagulation, which will form a thrombus, or blood clot.  This may block the vessel and lead to a 
heart attack(54).  Therefore, reducing oxidative stress may prevent the oxidation of LDL and 
prevent the inflammation that follows.   
Structural proteins may be significant factors as well. While too much collagen 
deposition can be negative, too little collagen content in the fibrous cap may put it at risk to 
rupture more easily and thus increase the risk of a cardiovascular event.  Mice lacking 
procollagen C-endopeptidase enhancer 2 (PCOLCE2) and the LDL receptor (LDLR), a protein 
involved in proper collagen metabolism, for example, had increased atherosclerosis compared to 
mice only lacking LDLR (55).   Learning of ways to prevent both excessive and deficient 
production of collagen in plaques may help to prevent against CVD events.    
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FIGURE 1.4.1.  Inflammation in Cardiovascular Disease 
 
 
Currently, great focus is placed on the cholesterol content of the blood contained within 
each class of lipoprotein.  Despite significant evidence suggesting more predictive markers of 
risk, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TG) are the main 
parameters used by primary care physicians to determine cardiovascular risk.  A major source of 
these associations is the Framingham Heart Health study, which revealed strong negative 
associations between HDL-C and CVD risk and strong positive associations between LDL-C and 
CVD risk(51).  However, therapies aimed at lowering LDL-C leave a large residual risk and 
therapies aimed at raising HDL-C have proven largely ineffective, suggesting that great 
complexities underlie these associations(5, 6). More recent research has revealed that there are 
many other qualities to lipoproteins that affect their atherogenicity other than the total amount 
cholesterol present in their fraction within blood. Factors such as lipoprotein particle size, 
15 
 
number, inflammatory status, surface protein concentrations, protein activity, and overall 
functionality may be more reliable predictors of risk than traditional methods(56). These 
aspectsof functionality can reveal a high level of risk where traditional methods would have 
estimated a low level of risk and vice versa.   
The complexity of HDL particle has become increasingly apparent over the last few 
decades of CVD research.  Drug interventions developed to raise HDL-C, such as niacin therapy, 
have successfully increased HDL-C concentration without reducing CVD risk(5, 6).  While 
traditionally thought to be an anti-inflammatory, anti-atherogenic particle, HDL is now thought 
to have the potential to become pro-inflammatory and pro-atherogenic in states of ill-health or 
disease(57).  Therefore, HDL function is gaining attention and is of particular interest.  HDL has 
many roles in the body including as an anti-inflammatory, anti-oxidative purpose, anti-
thrombotic, immune-supporting, and, of course, cholesterol-transporting particle(57).  Its role in 
cholesterol transport includes what is called reverse cholesterol transport (RCT) or the transport 
of cholesterol from peripheral tissues, such as the endothelium, back to the liver to be cleared.  
Many proteins on the surface of HDL have been associated with the particle’s inflammatory 
status and functionality and are thought to be accurate predictors of CVD risk.  Proteins like 
lecithin-cholesterol acyltransferase (LCAT)(58), apolipoprotein A1 (ApoA1)(59), and 
paraoxinase 1 (PON1)(60) are typically higher in amount on well-functioning, anti-inflammatory 
HDL while proteins like serum amyloid A (SAA)(61) and clusterin (CLU)(62) are typically 
higher in poorly-functioning, pro-inflammatory HDL.  LCAT esterifies free cholesterol to 
cholesterol esters and thus helps in the transport of cholesterol to the HDL and subsequently 
allows nascent (newly formed) HDL to become mature HDL.  ApoA1 is the major structural 
protein of HDL and allows HDL to form in the first place.  PON1 is a major anti-oxidant enzyme 
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on the surface of HDL that typically has a significant anti-atherosclerotic effect.  SAA is an acute 
phase response protein whose quantity increases significantly during inflammatory conditions.  
Clusterin, or apolipoprotein J, is another protein that increases in response to inflammation but is 
thought to be protective making interpretation of the meaning of its quantity somewhat 
difficult(63).Additionally, the activity of PON1 is thought to be more predictive of risk than the 
total amount of the protein(64).  Liver protein and gene expression can also be helpful in 
assessing HDL function.  The membrane receptor SRB1 is responsible for facilitating the uptake 
of lipid from the HDL particle into the liver and in that way it aids in the process of RCT(65).  
The transporter ABCA1 facilitates transport of lipid to lipid-poor ApoA1 proteins to form 
nascent HDL particles not only from the liver but from other tissues as well including from 
macrophages and the intestine(66).  By helping to form new HDL particles, ABCA1 encourages 
RCT.  It appears that methods to measure inflammatory status and HDL function may be 
particularly useful in more accurately estimating CVD risk. 
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FIGURE 1.4.2.HDL Function 
 
DIET  
 Diet is one means of reducing inflammation.  Altering macronutrients intakes can be 
one simple way of significantly reducing diet induced inflammation if the diet is poor.  For 
example, high fat diets have been shown to be inflammatory (67), and LPS may be one 
mechanism why (68).  The proportions of different types of fatty acids in the diet may be another 
dissimilarity between healthy and pro-inflammatory diets(38).  However, foods contain much 
more than macronutrients and quality of food in other ways may be important for encouraging 
health and preventing disease.  Fruits and vegetables are recommended by almost every diet, 
nutritionist, organization, or media outlet.  Fruits and vegetables intake is negatively associated 
with many different diseases, including cardiovascular disease and obesity (12, 13).  The vitamin 
and mineral content of fruits and vegetables is usually quite high and this may be one reason for 
their negative association with disease.  However, there are many other things in fruits and 
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vegetables and it is possible that any effect they may have on disease is partially due these other 
constituents.  Many of these other constituents fall into a category called dietary bioactives. 
DIETARY BIOACTIVES 
 Dietary bioactives are molecules present in foods that are not essential in the diet but can 
have an influence on health.  Dietary bioactives include zoochemicals, which nonessential 
animal molecules, and phytochemicals (or phytonutrients), which are nonessential molecules 
originating from plants.  Many of these chemicals may have biological significance despite the 
fact they are not essential.  One major class of phytochemicals, called polyphenols has been 
studied extensively for their potential therapeutic benefit to many diseases.  Phytochemicals may 
improve inflammation, insulin resistance, and atherosclerosis (69-71).  One class of polyphenols 
that is of particular interest is anthocyanins.   
ANTHOCYANINS 
 Anthocyanins are water soluble, blueish-purplish pigment molecules present in many 
foods, including dark-colored berries like blueberries, raspberries, boysenberries, etc.  Intestinal 
absorption of anthocyanins are extremely low (only about 1% of ingested anthocyanins can be 
detected in blood) (20) and so many have suggested their effects may be by merely reducing 
intestinal absorption.  However, anthocyanins are known to be cleaved by gut microbiota into 
metabolites that can be absorbed via the colon (21) and recently in 2013, Czank et al. were able 
to track the absorption and metabolism of a common anthocyanin, cyanidin-3-glucoside (C3G), 
using an isotopically labelled form of the compound in 8 male human subjects (72).  They were 
able to measure significant concentration in the serumand based on urine and breath excretion 
they estimated an average bioavailability of about 12.4%.This can be explained by the presence 
of metabolites, which likely responsible for many of the physiological effects of these dietary 
bioactives. 
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 Anthocyanins have been shown to reduce inflammation (15) so therefore may be 
beneficial in chronic diseases such as CVD and obesity.  The anthocyanin, C3G, fed to diet-
induced-obese (DIO) C57BL/6J and db/db mice at 0.2% of the diet for 5 weeks improved insulin 
sensitivity, steatosis, and inflammation(18).  Additionally, purified blueberry anthocyanins were 
fed to DIO-C57BL/6J mice for 10 weeks and reduced adiposity and fasting glucose(19).  C3G 
has also been shown to improve HDL function in mice (16) and anthocyanins have been shown 
to reduce atherosclerosis in mice (17). 
 As mentioned above anthocyanins likely have much of their effect through metabolites.  
C3G, an anthocyanin that is very common in nature, is known to be metabolized to a compound 
called protocatechuic acid (PCA) by the gut microbiota in the colon, where it can then be 
absorbed and enter the bloodstream (21).  The effects of C3G are greatly reduced in mice that are 
treated with antibiotics (73) suggesting that most of the effects of anthocyanins, or at least C3G, 
are in fact due to their absorbable metabolites.  It appears that anthocyanins may be beneficial for 
these disease states; however, people do not eat purified anthocyanins, so foods high in 
anthocyanins should be studied.   
BLACK ELDERBERRY  
 Black elderberry is one of the most abundant natural sources of anthocyanins (19, 24). 
The berry has been used for thousands of years in traditional medicine throughout European, 
Chinese,North African, and Native American societies(22, 23).  It was used for a wide array of 
ailments and spiritual efforts, including keeping evil spirits away, but it was often used in time of 
sickness and for its healing properties (74).  Native Americans used it to treat fever and 
rheumatism (75). The berry remains in use in Europe where it is incorporated into pies, beer and 
wine but despite all this history it is relatively unheard of in the United States.  It can sometimes 
be found in over-the-counter cold and flu medicine to support a “healthy immune response.” The 
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berry can be toxic when raw, depending on the variety but is safe to eat when processed or 
cooked.  Nevertheless, this toxic quality may be one reason it is not more commonly used or 
studied.  An American and a European variety exist; the American variety being native to the 
United States, while the European variety was introduced by settlers.  The European variety 
(SumbucusNigra) is more common but still is the focus of very little scientific research.  Several 
studies have demonstrated its potential therapeutic effect on the influenza virus (23, 76)and a 
2001 study investigating Sambucol, an elderberry containing cold and flu medicine, reported a 
stimulation of inflammatory cytokine production by human monocytes in vivo (77).  There is a 
lack of studies on the effect of black elderberry on chronic disease, however, and considering its 
long traditional use, an effort should be made to investigate this. 
CONCLUSION 
 In conclusion, there is reason to believe that black elderberry may be effective at treating 
inflammation in chronic diseases because of its abundance of anti-inflammatory anthocyanins.  
From studies of anthocyanins it is also likely that the berry may be especially beneficial in the 
disease states of CVD and obesity.  Black elderberry may be able to improve HDL function as 
well as limit atherosclerosis in CVD and may be able to lower lipotoxicity and metabolic 
dysfunction in obesity thereby improving glucose control, inflammatory status and the risk of 
obesity-related comorbidities.   
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Chapter 2: Anthocyanin-rich Black Elderberry 
Extract Improves Markers of HDL Function and 
Reduces Aortic Cholesterol in Hyperlipidemic Mice 
This chapter is published in the format published: 
Farrell N, Norris G, Lee SG, Chun OK, Blesso CN.Anthocyanin-rich black elderberry extract 
improves markers of HDL function and reduces aortic cholesterol in hyperlipidemic mice.Food 
Funct. 2015 Apr 8;6(4):1278-87. 
 
Introduction 
As the leading cause of death worldwide, cardiovascular disease (CVD) claims upwards of 17 
million lives each year(78).  Among risk factors, plasma low-density lipoprotein-cholesterol 
(LDL-C) is strongly positively associated with CVD(79) and is considered a primary target for 
its prevention (80). Despite aggressive lowering of LDL-C, there still exists a residual risk of 
cardiovascular events in patients with established coronary heart disease (CHD)(81). In contrast 
to LDL-C, high-density lipoprotein-cholesterol (HDL-C) levels are strongly negatively 
associated with future risk of CHD (82-85). HDL is thought to reduce atherosclerosis, a major 
contributor to CVD, through its ability to remove excess lipid from the artery and transport it 
back to the liver for excretion from the body, a pathway termed “reverse cholesterol transport” 
(RCT)(86). Beyond its role in RCT, HDL is thought to have anti-inflammatory, antioxidant, and 
anti-thrombotic activities, and modulate the immune system(87-89).  The atheroprotective effect 
of HDL is mainly attributed to its role in RCT, with plasma HDL-C considered to be a surrogate 
metric for this pathway. HDL-C is a commonly used marker in the clinical setting because of the 
observation that HDL-C negatively correlates with CVD risk. Therapies aimed at increasing 
HDL-C are under intense investigation in the hope of preventing future cardiovascular events (5, 
90).  However, several recent studies have put this “HDL hypothesis” under questioning, 
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suggesting that higher HDL-C may not always equal lower risk (5, 91, 92).  It is thought that 
HDL has the potential to become dysfunctional and even pro-inflammatory. In certain 
inflammatory disease states, HDL particles become pro-atherogenic(93), and may explain 
residual CHD risk in those with high HDL-C(94). Thus, it is believed that HDL function or 
quality rather than HDL quantity most effectively communicates risk.   
 HDL surface proteins will vary in states of health and disease, bothin quantity and 
activity (95-97). Paraoxonase-1 (PON1) is a protein that is incorporated onto human HDL and is 
thought to contribute greatly to the anti-atherosclerotic effects of HDL (98).  PON1 can act as an 
antioxidant enzyme and its activity is positively correlated with HDL function and negatively 
correlated with CVD risk (99-101).  Inflammatory conditions, such as atherosclerosis, can 
remodel HDL to a pro-inflammatory particle with impaired antioxidant activity and 
compositional changes consisting of elevated serum amyloid A (SAA), an acute phase protein, 
and reduced PON1(102). Other proteins carried on HDL that are important for its 
atheroprotective functions include apolipoprotein A-I (apoA-I)(103), clusterin/apolipoprotein J 
(Clu)(63), lecithin-cholesterol acyltransferase (LCAT)(104) , and procollagen C-endopeptidase 
enhancer-2 (PCOLCE2)(105).  
 While there has been a significant effort to develop HDL-targeted drug therapies, 
research on how the intake of foods or specific nutrients affect HDL function is lacking. Because 
many HDL raising drugs cause significant side effects or fail to reduce CVD risk, natural 
alternatives are needed. Anthocyanins are a class of polyphenols that have been shown to 
increase plasma HDL-C, PON1 activity, and cholesterol efflux capacity of serum in humans(16, 
106). Among the highest concentrations of anthocyanins in foods are reported to be found in 
black elderberry (Sambucusnigra)(107). Elderberries are most commonly used as ingredients in a 
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variety of processed foods and beverages, but have also been used medicinally for hundreds of 
years in Chinese medicine and other cultures(108). Approximately 85% of its anthocyanin 
content is comprised of cyanidin 3-glucoside (C3G) and cyanidin 3-sambubioside (C3S)(109).  
While traditional medicinal use of elderberry has been described for centuries, there has been 
surprisingly little research on the effects of black elderberry consumption on chronic disease. We 
therefore investigated the effects of an anthocyanin-rich black elderberry extract (BEE) on 
preventing HDL dysfunction and atherosclerosis in a hyperlipidemic animal model that has 
impaired HDL functionality – apoE-/-mice (110-112). We hypothesized that black elderberry 
extract can prevent the development of dysfunctional HDL and prevent atherosclerosis 
progression in this mouse model.   
Materials and Methods 
EXTRACTION AND HPLC ANALYSIS OF ANTHOCYANINS 
Spray-dried BEE (Sambucusnigra) (standardized to 13% anthocyanins) was kindly provided by 
Artemis International (Fort Wayne, IN.). Cyanidin 3-glucoside (C3G) standard, formic acid, 
acetonitrile, and methanol were obtained from Sigma-Aldrich (St. Louis, MO). Cyanidin 3-
sambubioside (C3S) standard was obtained from Extrasynthese (Genay, France). All solvents 
used were of HPLC-grade, filtered, and degassed before use. The content of major anthocyanins 
of BEE was determined by reversed-phase high-pressure liquid chromatography (HPLC) with 
the method previously described with slight modification(113). Briefly, dried BEE was dissolved 
in acidified methanol with 0.1% HCl (v/v) and syringe-filtered to obtain a purified solution. 
Reversed-phase separation was performed on an Agilent 1200 HPLC system (Agilent 
Technologies, Palo Alto, CA,) equipped with a UV-Vis diode array detector, column oven, and 
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C18 reversed-phase Agilent Zorbax column (5 µm, 250 mm × 4.6 mm; Agilent Technologies, 
Palo Alto, CA,). BEE anthocyanins were separated using a mobile phase gradient (solvent A, 5% 
aqueous formic acid, solvent B, 5% formic acid in absolute acetonitrile) at a flow rate of 0.9 
mL/min. Column temperature was maintained at 13°C during the analysis. Anthocyanins were 
detected at 520 nm and identified by comparing the spectra and retention times to C3G and C3S 
standards (≥95% pure HPLC-grade).  
ANIMALS AND DIETS 
FIGURE2.2.1. Study Design 
 
ApoE-/- mice were used as an atherosclerosis model. ApoE-/- mice have elevated blood 
cholesterol concentrations compared to wild-type mice and spontaneously develop 
atherosclerosis over time(110, 112). Male apoE-/- mice (8 weeks of age, n = 24) were obtained 
from The Jackson Laboratory (Bar Harbor, ME) and allowed to acclimate to the animal facility 
for 2 weeks. Mice were then fed for 6 weeks either a purified AIN-93M diet (Harlan Teklad; 
TD.94048) (Control, n = 12) or the same diet modified to contain 1.25% (w/w) of BEE (BEE, n 
= 12). Carbohydrate content was adjusted to match control diet composition by replacing 
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maltodextrin with BEE. A single batch of BEE was obtained from the supplier and was 
compositionally characterized with regards to anthocyanins and polyphenols. The diets were 
prepared as single batches and kept in vacuum-sealed packaging at -20ºC until feeding. The 
1.25% BEE (w/w) diet equals a mouse dose of approximately 200 mg of anthocyanin/kg of body 
weight, which corresponds to a 70 kg human consuming ~75 g of black elderberry per day (~950 
mg anthocyanin(114)) based on body surface normalization(115). Food intake and body weight 
were assessed weekly. Old food was discarded and replaced with fresh diet twice per week. Mice 
were fasted for 6-8 hr prior to being anesthetized with ketamine/xylazine (100 mg/kg ketamine 
and 10 mg/kg xylazine) followed by blood collection by cardiac puncture and euthanasia. Blood 
was allowed to clot at room temperature for 30 minutes before serum separation by 
centrifugation (10,000 x g for 10 minutes at 4°C) and then stored frozen at -80°C. Tissues were 
perfused with saline, and intestine and liver tissues were harvested, snap-frozen in liquid 
nitrogen and stored at -80˚C. Thoracic aorta and heart were fixed in 10% neutral-buffered 
formalin for at least 48 hours prior to analysis. All mice were housed in a temperature-controlled 
room and maintained in a 12 hr light/12 hr dark cycle at the University of Connecticut-Storrs 
vivarium. The Animal Care and Use Committee of the University of Connecticut-Storrs 
approved all procedures used in the current study. 
SERUM BIOCHEMICAL ANALYSIS 
Total cholesterol, HDL-C, triglycerides, glucose, ALT, and AST were measured using enzymatic 
assays. Apolipoprotein (apo)B-containing lipoproteins were removed prior to HDL-C analysis 
via dextran sulfate/Mg2+ precipitation methods(116). Lipid enzymatic kits and HDL-cholesterol 
precipitating reagent were purchased from Wako Diagnostics (Richmond, VA) and Stanbio 
Laboratory (Boerne, TX), respectively. Alanine aminotransferase (ALT) and aspartate 
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aminotransferase (AST) reagents were purchased from Pointe Scientific, Inc. (Canton, MI). 
Serum inflammatory markers were examined by Luminex/xMAP magnetic bead-based 
multiplexing assays using MAGPIX instrumentation (EMD Millipore, Billerica, MA). 
 Serum and hepatic lipid peroxidation products were assessed by thiobarbituric acid 
reactive substances (TBARS) assay(117). After precipitation of non-lipid TBARS with ice-cold 
10% (w/v) trichloroacetic acid, 0.33% TBA (w/v) was added to the supernatant, boiled for 10 
min, and fluorescence read at 530 nm excitation and 550 emission on a fluorescence microplate 
reader (BioTek, Winooski, VT). 
 PON1 activity towards phenyl acetate (arylesterase activity) was examined in serum. 
Samples were diluted 400-fold in assay buffer (50 mMTris, 1 mM CaCl2, pH 8.0) and then added 
in duplicate to a UV-compatible half-area 96-well plate (Corning Inc., Corning, NY). Next, 
substrate buffer (3 mM phenyl acetate, 50 mMTris, 1 mM CaCl2, pH 8.0) was added to each well 
and measured at 270 nm every 20 seconds (25°C) for 3 minutes using a microplate 
spectrophotometer. After correcting for non-enzymatic hydrolysis of phenyl acetate, results were 
expressed as kU/L using the molar extinction coefficient of phenol (1310M-1cm-1).  
 HDL antioxidative capacity was measured using a modification of the methods of 
Kelesidis et al.(118). Briefly, apoB-depleted serum (0.5 µg cholesterol) was incubated with 15 
µM dihydrorhodamine (DHR) 123 (Life Technologies, Carlsbad, CA) and 150 µM of 2,2′-
azobis(2-methylpropionamidine) dihydrochloride (AAPH) (Sigma-Aldrich, St. Louis, MO) to 
initiate oxidation. The oxidation of DHR was monitored every 2 minutes for 1 hour by 
measuring fluorescence at excitation wavelength of 500 nm and emission wavelength of 536 nm. 
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TISSUE LIPID EXTRACTION AND ANALYSIS 
Hepatic lipids were extracted with chloroform: methanol (2:1), dried under nitrogen at 60°C, 
solubilized in Triton X-100, and assayed for total cholesterol, free cholesterol, phospholipids, 
and triglycerides by enzymatic methods(119). Cholesteryl ester (CE) content was calculated as 
CE = (TC-FC) ×1.67. For aortic cholesterol quantitation, perfused aorta was first formalin fixed 
and then thoroughly cleaned of excess fat tissue under a stereo microscope. Lipids were 
extracted from the aortic arch and thoracic aorta with chloroform: methanol (2:1), dried under 
nitrogen at 60°C, and solubilized in Triton X-100(119, 120). Total cholesterol content was then 
determined by enzymatic methods. After extraction, delipidated aortas were digested in 1 N 
NaOH and total protein content per aorta was measured by bicinchoninic acid assay (Thermo 
Fisher Scientific, Waltham, MA.). Aortic cholesterol was expressed as µg per mg protein(120).  
RNA ISOLATION, CDNA SYNTHESIS AND QRT-PCR 
Total RNA was isolated from tissues using TRIzol reagent (Life Technologies, Carlsbad, CA), 
DNase I-treated, and reverse transcribed using iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA). Gene expression was measured by real time qRT-PCR using iTaq Universal SYBR Green 
Supermix (Bio-Rad,Hercules, CA) and a CFX96 real-time PCR detection system (Bio-
Rad,Hercules, CA). Primer sequences used for qRT-PCR analysis are listed in Supplementary 
Table 1 (Table S1). Gapdh and Rplp0 served as internal control genes and the geometric mean 
was used for normalization(121). Fold expression relative to the internal control genes was 
calculated using the 2−∆∆Ct method(122). 
SDS-PAGE AND IMMUNOBLOTTING 
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Serum aliquots were diluted with 4X LDS sample buffer (Life Technologies, Carlsbad, CA) 
containing 250 mMdithiothreitol (DTT) added as a reducing agent. Samples were heated at 70°C 
for 10 minutes and then proteins were separated by 4-20% SDS-PAGE (Bio-Rad TGX Stain-
Free). TGX Stain-Free gels were subsequently UV-activated using a ChemiDoc XRS+ imaging 
system (Bio-Rad,Hercules, CA) and transferred to PVDF membrane, after equilibration in 
methanol, using a semi-dry blot system and Tris-glycine buffer (pH 8.3). PVDF membranes were 
subsequently imaged for Stain-Free total protein and then blocked with 5% (w/v) non-fat dry 
milk solution (20 mMTris, 0.05% Tween-20, pH 7.4) for 2 hours. Primary antibodies for apoA-I 
and PON1 were diluted 1:5,000 and used for immunoblotting. All primary antibodies were 
purchased from Abcam (Cambridge, England). PVDF membranes were incubated with primary 
antibodies at 4˚C overnight, washed, and then incubated with an HRP-conjugated IgG secondary 
antibody (Life Technologies,Carlsbad, CA) for 1 hour at room temperature. Blots were incubated 
with chemiluminescence substrate and then visualized with a ChemiDoc XRS+ imaging system. 
Densitometry analysis was performed using Bio-Rad ImageLab 5.1 software and band intensity 
was normalized to Stain-Free total protein(123). 
STATISTICAL ANALYSIS 
Differences between groups were evaluated by independent t tests (p< 0.05 deemed significant). 
Bivariate Pearson correlations were used to assess relationships between biochemical measures. 
All statistical analysis was done using GraphPad Prism version 6 software. Data are reported as 
mean ± SEM.  
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Results 
MAJOR ANTHOCYANINS IN THE BEE 
The anthocyanin-rich BEE was found to be high in C3G and C3S (Table 1; Figure S1), 
contributing approximately 13.5% of the total dry weight of the extract. A minor anthocyanin 
peak was also present in the spectra and was likely cyanidin 3-sambubioside-5-glucoside, which 
has been found in black elderberry previously(124). 
TABLE 2.3.1. Major anthocyanins in black elderberry extract 
Anthocyanins Content (mg/g dry weight) 
Cyanidin 3-glucoside 38.01 ± 0.34 
Cyanidin 3-sambubioside 97.97 ± 0.16 
Each value represents the mean ± SEM, n = 3. 
 
FIGURE 2.3.1 HPLC Spectra of BEE Anthocyanins 
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EFFECTS OF BEE ON FOOD INTAKE AND BODY WEIGHT 
We investigated the effects of black elderberry in a hyperlipidemic mouse model by feeding 
male apoE-/- mice for 6 weeks either a control AIN-93M diet or the same diet with 1.25% (w/w) 
BEE added. After 6 weeks, no differences were observed between the control and BEE-fed 
groups for food intake (3.49 ± 0.11 g vs. 3.47 ± 0.06 g, p = 0.8), body weight (27.7 ± 0.6 g vs. 
28.2 ± 0.5 g, p = 0.8), or liver weight (Table 2).  
TABLE 2.3.2. Metabolic and liver markers of ApoE-/- mice after 6 wk 
Variables Control BEE 
Total Cholesterol, mg/dL 403.4 ± 27.9 419.8 ± 21.5 
HDL-Cholesterol, mg/dL 25.0 ± 2.4 27.2 ± 1.6 
Triglycerides, mg/dL 90.6 ± 9.1 94.1 ± 4.2 
Glucose, mg/dL 168.5 ± 5.3a 145.4 ± 3.9b 
Serum TBARS, µM 1.3 ± 0.1 0.9 ± 0.2 
ALT, IU/L 33.4 ± 4.8 25.4 ± 6.5 
AST, IU/L 71.8 ± 4.4a 53.0 ± 4.8b 
Liver Weight, g 1.09 ± 0.03 1.14 ± 0.05 
Relative Liver Weight, %  4.0 ± 0.1 4.1 ± 0.1 
  
 
 
 
 
Each value represents the mean ± SEM of values from n = 12 mice 
per group. 10 week old male apoE-/- mice were fed indicated diets for 
6 weeks. Superscripts with different letters indicate significant 
differences at p<0.05. ALT, alanine transaminase; AST, aspartate 
transaminase; Control, AIN-93M purified diet; BEE, black elderberry 
extract-supplemented AIN-93M; HDL, high density lipoprotein; 
TBARS, thiobarbituric acid reactive substances. 
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BEE DOES NOT ALTER PLASMA LIPIDS BUT IMPROVES OTHER METABOLIC 
MARKERS 
Serum and liver markers of mice after 6 weeks are presented in Table 2. Fasting lipids did not 
differ between groups at the end of the study. Fasting glucose was significantly lower in the 
BEE-fed mice, while serum lipid peroxidation measured as TBARS tended to be lower in the 
BEE-fed mice (p = 0.09). In contrast, hepatic TBARS were not significantly different between 
groups (data not shown). Serum AST and ALT, markers of liver damage, tended to be lower in 
BEE-fed mice; however, only serum AST was significantly different compared to control (p = 
0.01).  
ALTERATION OF CHOLESTEROL AND HDL FUNCTION-ASSOCIATED GENE 
EXPRESSION WITH BEE 
We next examined the effects of BEE on hepatic measures of cholesterol metabolism and HDL 
function. Hepatic lipids were extracted and enzymatically assayed for cholesterol, free 
cholesterol, triglycerides, and phospholipids. As shown in Figure 1A, hepatic lipids did not 
differ significantly between groups after 6 weeks on the diets. Although hepatic lipids were 
unchanged with BEE, we observed significant alterations in the expression of genes related to 
cholesterol homeostasis and HDL function (Figure 1B). Hepatic mRNA changes with BEE-
feeding were consistent with an improvement in HDL function (increased Pon1 and LCAT; 
decreased Saa1 andClu) and a reduction in hepatic cholesterol levels (increased Ldlrand Hmgcr; 
reduced Cyp7a1). With BEE-feeding, hepatic Saa1 expression was reduced by ~10-fold, whereas 
Pon1 and Lcat were increased by ~2-fold and ~1.5-fold, respectively. Hepatic Clu, the gene 
which encodes clusterin and also known as apolipoprotein J, was non-significantly (p = 0.08) 
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reduced by ~1.6-fold with BEE. Pcolce2, a gene which has recently been implicated in HDL 
metabolism and function(105), was reduced by ~1.6-fold in the BEE-fed mice. This data 
suggests BEE-feeding prevents alterations in HDL-related gene expression in the liver that may 
contribute to HDL dysfunction. In addition to changes in genes related to HDL function, mice 
fed BEE displayed significant increases in Hmgcr (~1.75-fold) and Ldlr (~2-fold). A ~2.8-fold 
reduction in Cyp7a1 expression was also found in BEE-fed mice. We did not observe any 
significant differences in the gene expression of transcription factors that regulate cholesterol 
homeostasis in the liver (LXR, Srebf2, and Shp). Although hepatic lipid measures did not 
change, there were still several significant sterol-regulated gene expression changes in the liver, 
suggesting that BEE potentially alters sterol metabolism or compartmentalization in the liver. 
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FIGURE 2.3.2Hepatic Lipids and mRNA 
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BEE INCREASES PARAOXONASE-1 ACTIVITY BUT DOES NOT ALTER APOB-
DEPLETED SERUM ANTIOXIDATIVE CAPACITY 
Since BEE resulted in a ~2-fold increase in hepatic Pon1 expression, we examined enzyme 
activity and protein abundance. We measured PON1 antioxidant activity via its arylesterase 
activity towards phenyl acetate. As shown in Figure 2A, serum arylesterase activity was 
significantly increased in whole serum of BEE-fed mice. We further examined PON1 status by 
assessing protein abundance in serum by immunoblotting (Figure 2B). While there was no 
significance difference in serum PON1 abundance, there was a trend for higher PON1 in the 
BEE mice (p = 0.10). This data suggests that BEE may facilitate favorable changes in HDL to 
promote PON1 activity. We further examined HDL antioxidant function by measuring the ability 
of apoB-depleted serum to prevent DHR oxidation. We did not observe a significant difference 
between groups for this measure of HDL antioxidative capacity (data not shown). 
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FIGURE 2.3.3Serum PON1 Activity and Protein Levels 
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BEE FEEDING INCREASES INTESTINAL APOA-I EXPRESSION WITH NO EFFECT 
ON SERUM APOA-I 
Since BEE-feeding resulted in many significant changes in hepatic gene expression, we 
examined gene expression of cholesterol and HDL-related genes in the small intestine (Figure 
3A). BEE-feeding induced Ldlr (p = 0.05) in the small intestine similarly to the liver. In contrast 
to the liver, apoa1 was significantly increased by ~1.7-fold in the small intestine of BEE-fed 
mice (p = 0.04). We next examined apoA-I protein abundance in serum (Figure 3B) by 
immunoblotting. We found no significant difference in whole serum apoA-I between groups. 
However, apoE-/- mice accumulate significant amounts of apoA-I on circulating remnant 
lipoproteins in addition to HDL(125). When serum was apoB-depleted, BEE-fed mice tended to 
have higher HDL-apoA-I protein abundance, but this difference was not significant (p = 0.14).   
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FIGURE 2.3.4Small Intestine mRNAand Serum Apoa1 Protein
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BEE REDUCES SERUM MCP1 AND AORTIC CHOLESTEROL ACCUMULATION 
We next sought to determine whether BEE-feeding could alter markers of systemic inflammation 
and atherosclerosis progression (Figure 4). BEE-fed mice had significantly lower MCP1 (also 
known as MCP-1) and tended to have lower serum markers of inflammation overall (Figure 
4A). Total cholesterol content of the aortic lipid extract was examined as a biochemical measure 
of atherosclerosis, which is a reasonable substitute for morphometric analysis(126). BEE-fed 
mice had significantly lower cholesterol content of the aorta (Figure 4B,p = 0.03), suggesting 
the extract reduced atherosclerosis progression in these animals. Furthermore, we noted a 
significant inverse relationship between PON1 arylesterase activity in serum and aortic 
cholesterol content (r = -0.71, p = 0.0002, Figure S2). 
FIGURE 2.3.5 Serum Inflammatory Markers and Aortic Cholesterol 
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FIGURE 2.3.6 Pearson Correlation of Serum Arylesterase Activity and Aortic Cholesterol 
 
Discussion 
The identification of atherogenic HDL, associated with certain disease states, provides a 
greater appreciation of HDL metabolism and a potential therapeutic target beyond simple HDL-
C content. Several HDL functional assays have been developed and found to be significant 
independent predictors of disease risk (e.g., PON1 activity(101)) or indicators of disease status 
(e.g., anti-inflammatory assays(118) ). However, how dietary components such as polyphenol-
rich foods influence HDL functionality is not well understood. In the current study, apoE-/- mice 
fed BEE displayed less aortic cholesterol, but in the absence of changes in plasma lipids and with 
only modest changes in serum inflammation markers. However, BEE-fed mice had significantly 
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increased serum PON1 activity and displayed significant changes in hepatic gene expression that 
encode for HDL proteins, suggesting an influence on HDL function. 
BEE-fed mice displayed significant increases in hepatic Pon1 expression and PON1 
arylesterase activity. PON1 is an HDL-associated enzyme thought to play a large role in the 
ability of HDL to inhibit LDL oxidation(127) and is an independent risk factor for CHD 
events(101). The activity of PON1 in serum is responsive to diet; polyphenols from grapes(128) 
and pomegranate(129) have been shown to increase PON1 activity, and its association with 
HDL. Mixed anthocyanins were also shown to increase serum PON1 activity, HDL-C and 
cholesterol efflux capacity in dyslipidemic patients(106).ApoE-/- mice have lower PON1 activity 
than wild-type mice that decreases further with age(98) – which may be related to the 
atherosclerotic disease process or the function of apoE in PON1 stability and activity. ApoE-/- 
mice also present with increased systemic and hepatic inflammation(130) and pro-inflammatory 
HDL(111). BEE appeared to protect mice from the loss of PON1 functionality that occurs with 
aging and which may be due to hepatic inflammation. At this point, the mechanism of how BEE 
affects Pon1 expression remains unclear, but could be due to attenuation of inflammation(102). 
In addition to Pon1, other hepatic gene expression related to HDL function changed with BEE 
feeding, including SAA, LCAT, clusterin (p = 0.08), and Pcolce2. Hepatic SAA(102) and 
clusterin (apolipoprotein J)(131) are induced with inflammation, while LCAT gene expression is 
generally reduced(132). Saa1 is known to be reciprocally regulated with Pon1 during 
inflammation(102), and levels in serum have been shown to positively correlate with HDL 
inflammatory properties in rabbits(133). PCOLCE2 is a secreted glycoprotein that has been 
positively associated with HDL cholesterol efflux capacity in mice(105). We observed a 
significant reduction in hepatic Pcolce2 expression in BEE-fed mice, suggesting a negative 
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effect on HDL function. However, it has also been found that silencing PCOLCE2 expression in 
HepG2 cells markedly increases apoA-I secretion(134), so its role in HDL metabolism appears to 
be complex and unresolved.   
 Consumption of anthocyanin-rich foods has been associated with reduced CVD 
mortality(135). Human studies in subjects with clinically diagnosed disease have demonstrated 
improvements in inflammationwith relatively moderate dosages of anthocyanins (<100 
mg/day)(136). We observed significantly lower MCP1 levels in serum of BEE-fed mice, a 
chemokine with clear detrimental effects on atherosclerosis(137) and a mediator of pro-
inflammatory HDL(138).  Furthermore, with the reduction in hepatic Saa1 and serum AST, BEE 
may have alleviated hepatic inflammation, which has been noted in apoE-/- mice. Black 
elderberry, as a source of dietary bioactives, has been linked to possible health benefits related to 
stimulation of the immune system and anti-viral properties(139). However, very little research 
has been done to examine elderberry’s effects on lipid metabolism or in chronic disease models. 
In the few animal studies reported, feeding black elderberry has positively impacted plasma 
cholesterol levels in some(140), but not all cases(141). Although we observed significant 
alterations in hepatic cholesterol homeostatic gene expression, there were no significant 
differences in serum cholesterol levels between groups. Generally, an induction in Ldlr 
expression would be associated with reductions in blood cholesterol, although there is important 
post-translational regulation of the receptor that may attenuate this relationship(142). Our 
explanation for the lack of blood cholesterol changes may be due to the animal model under 
study, the apoE-/- mouse. The apoE-/- mouse might not be a suitable model to detect differences 
in blood cholesterol due to LDL-R modulation(143). Despite no changes in traditional 
lipoprotein risk factors, we observed a significant reduction in aortic cholesterol content in the 
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BEE-fed mice. Aortic cholesterol content was strongly inversely associated with PON1 
arylesterase activity in this study; therefore, differences in PON1 between groups may have been 
an important factor in aortic cholesterol accumulation. Aortic cholesterol content is considered 
an acceptable biochemical substitute for morphometric analysis to quantitate atherosclerosis in 
mice(120, 126). Thus, it appears that BEE halted the progression of atherosclerosis normally 
observed with aging in these animals.  
Although there are many nutrients in black elderberries, the health promoting effects of 
the berry are generally attributed to its high anthocyanin content. Compared to other berries, 
black elderberry is exceptionally high in cyanidins, and in particular, C3S and C3G. C3S is not 
found in appreciable amounts in other berries(144). C3G is more widely distributed, however, 
the highest concentration of C3G in foods is reportedly in black elderberry (794 mg/100g)(107). 
C3G has been shown to improve several features of HDL reverse cholesterol transport in cell and 
animal studies. Oral gavage of C3G (50 mg/kg body weight) to apoE-/- mice for 4 weeks resulted 
in elevated plasma HDL-C, apoA-I, increased RCT, and a reduction in atherosclerosis(73). More 
research is warranted to determine if BEE influences cellular cholesterol efflux of macrophages 
and reverse cholesterol transport. 
Our findings are consistent with the effects observed of other dark colored berries in 
animal models of atherosclerosis (Table 2.4.1).  The 20 percent reduction in aortic cholesterol 
after six weeks is comparable to the 26.7 percent reduction in macrophage foam cells reported by 
Vinson et al. in 2001 after 4 weeks of grape juice feeding in hamsters.  It is also reasonable in 
comparison to a 41 percent reduction in atherosclerotic legion area reported by Fuhrman et al. in 
2005 after 10 weeks of grape powder feeding in ApoE(-/-) mice, and a 33 percent reduction in 
aortic cholesterol reported by Zern et al. in 2003 after 12 weeks of grape powder feeding in 
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guinea pigs, when considering the fact that the current study was only six weeks of intervention. 
The reported 15 percent increase in PON1 arylesterase activity in this study compares well to the 
25 percent increase in PON1 activity after 20 weeks of blueberry feeding in ApoE(-/-) mice 
reported by Wu et al. in 2010, when considering the longer duration of the 2010 study.  Changes 
in plasma lipids with treatment of anthocyanin-rich berries are typically variable. For example, in 
2001 Vinson et al. reported grape juice feeding resulted in 27 percent lower TC and 37 percent 
lower LDL in hamsters but in 2010, Wu et al. reported 13.3 and 14.5 percent higher TC and 
LDL, respectively, after 20 weeks of dried blueberry feeding in ApoE(-/-) mice.  It’s likely that 
the reason that this study did not see any changes in plasma lipids was because of its short 
duration.  
TABLE 2.4.1 Related CVD Findings with Anthocyanin Feeding 
Author 
(Year) 
Berry Objective Design Findings 
Wu et al.  
(2010)53 
Lowbush 
blueberry 
Blueberry on 
atherosclerosis 
and oxidative 
stress in 
ApoE(-/-) 
mice 
Freeze-dried whole 
blueberry powder (BB) at 
1% or CTL fed for 20 
weeks.  Oil Red O staining 
of aortic sinus 
cryosections 
BB-fed mice had 39% lower 
mean atherosclerotic legion 
area.  TC and LDL 13.3% and 
14.5% higher in BB-fed mice 
respectively.  Serum PON1 
activity about 25% higher in 
BB-fed mice 
Xie et al.  
(2011)54 
Lowbush 
blueberry 
Blueberry on 
scavenger 
receptor 
activity in 
ApoE(-/-) 
mice 
Freeze-dried whole 
blueberry powder (BB) at 
1% or CTL fed for 20 
weeks 
Significantly lower CD36 and 
SR-A in BB-fed mice.  CD36 
and SR-A gene expression 
about 70% and 60% lower in 
aorta of BB-fed mice.  
Approximately 50% reduction 
of  CD36 and SR-A gene 
expression in peritoneal 
macrophages of BB-fed mice 
Mauray et 
al. (2012)55 
bilberry Bilberry 
extract on 
genes related 
to 
atherosclerosis 
ApoE(-/-) mice fed CTL 
diet or 0.02% bilberry 
extract (BE) for 2 weeks 
TC 20% lower in BE-fed mice.  
Down-regulation of genes 
associated with oxidative 
stress, adhesion molecules and 
angiogenesis in BE-fed mice.  
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Up-regulation of genes 
associated with decreased 
paracellular permeability in 
BE-fed mice 
Fuhrman 
et al. 
(2005)56 
Grapes Grape powder 
on 
atherosclerosis 
development 
in ApoE(-/-) 
mice 
ApoE(-/-) mice fed 
30mg/d freeze-dried grape 
powder (GP) in drinking 
water 10g/d for 10 weeks.  
Placebo as 
glucose:fructose 1:1 in 
drinking water 10g/d.  
Control as plain drinking 
water.  Atherosclerosis 
defined as area of lesions 
after staining of transverse 
sections of aortic arch 
only stained with osmium 
tetroxide under light 
microscopy 
Atherosclerotic lesions 41% 
lower in GP mice.  Serum 
oxidative stress and 
antioxidant capacity 8% lower 
and 22% higher respectively in 
GP mice relative to control.  
33% less macrophage uptake 
of oxidized LDL and 25% less 
oxidation of LDL by 
macrophages in GP mice 
compared to control 
Vinson et 
al. (2001)57 
Grapes Grape juice on 
atherosclerosis 
in hamsters 
Hamsters given access to 
Welches grape juice 
(GJ)(no Vitamin C) for 4 
weeks.  CTL group given 
water sweeten with 
artificial sweetener.   
Aortas fixed in 10% 
formaldehyde, 
mononuclear cells and 
macrophage-foam cells 
counted at 400X 
magnification and 
calculated per mm2 aorta 
to quantify atherosclerosis 
26.8% lower TC in GJ-mice.  
36.8% lower LDL in GJ-mice.  
26.7% less atherosclerosis in 
GJ-mice. 14% lower plasma 
lipid peroxides in GJ-mice. 
82% longer lag time of ex-vivo 
LDL oxidation in GJ-mice 
Zern et al. 
(2003)58 
Grape Grape powder 
(GP) on 
plasma lipids 
and cholesterol 
in aorta 
Female guinea pigs were 
fed high cholesterol 
(0.33g/100g) control diet 
or high cholesterol diet 
with grape powder 
(10g/100g) for 12 weeks.  
Aortic lipids were 
extracted using 
chloroform/methanol from 
0.1g of aortic arch 
Triglycerides and VLDL 39% 
and 50% lower, respectively, 
in GP fed guinea pigs 
compared to controls.  LDL 
was 50% and 38% lower in 
triglycerides and 
phospholipids, respectively, in 
GP fed guinea pigs.  Hepatic 
acyl 
CoA:cholesterylacyltransferase 
activity was 27% lower in GP 
fed guinea pigs.  Cholesterol 
accumulation in aorta was 33% 
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lower in GP fed guinea pigs 
 
We recognize the limitations of using mice as models of human HDL metabolism. Mice 
lack cholesteryl ester transfer protein (CETP) activity in plasma, and wild-type mice carry the 
majority of circulating cholesterol in HDL particles. However, apoE-/- mice spontaneously 
develop HDL characteristic of acute-phase inflammatory HDL observed in human 
atherosclerosis, with enrichment in clusterin and serum amyloid A and reductions in PON1(131). 
One limitation of using apoE-/- mice to study HDL is the appearance of apoA-I in non-HDL 
lipoprotein fractions, such as VLDL and LDL(125). Thus, apoA-I concentrations should be 
evaluated in both whole serum and HDL fractions in this mouse model. 
In conclusion, feeding BEE to apoE-/- mice resulted in improvements in serum MCP1, 
tissue and serum markers of HDL function, and a reduction in aortic cholesterol.  Further 
research is warranted to determine the mechanisms underlying the observed beneficial effects, 
such as the molecular pathways involved, and whether BEE can influence in vivo reverse 
cholesterol transport or other aspects of HDL function. Additionally, studies in apoE-/- mice of 
longer duration or with atherogenic diets would allow for the evaluation of BEE on complex and 
advanced atherosclerotic lesion development, which would contribute to our understanding of 
how diet affects the atherosclerosis phenotype. Overall, we believe this study provides insight 
into novel functional food properties of black elderberry, and potentially other foods rich in 
anthocyanins. However, it will be critical to study the effects of black elderberry on HDL 
function in humans, as mice display significant differences in HDL metabolism. 
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Chapter 3: Black Elderberry Extract Ameliorates 
Inflammation and Metabolic Dysfunction in Diet-
Induced Obese C57BL/6J Mice 
 
Introduction 
According to the World Health Organization, estimated worldwide rates of overweight and 
obesity are39% and 13%, respectively(26).  Obese individuals have shortened life expectancies 
(145); however, they do not typically die of obesity itself but rather obesity-related 
comorbidities, such as cardiovascular disease, diabetes, and certain types of cancers(146, 147).  
The adipose dysfunction and excessive ectopic lipid accumulation in tissues in obesity promotes 
an inflammatory state that is thought to be an underlying cause of these obesity-related 
comorbidities(148, 149). Therefore, methods that target and lower inflammation maybe effective 
at preventing obesity-related comorbidities.  Anthocyanins, a class of polyphenol belonging to 
the flavonoid family, are dietary bioactives whose intake has been shown to be inversely 
associated with inflammation and insulin resistance (150).  Cyanidin 3-glucoside (C3G), a major 
anthocyanin in nature, has been shown to enhance adipocyte function and protect adipocytes 
from metabolic stress in vitro, via enhancing peroxisome proliferator-activated receptor γ 
(PPARγ) activity and inhibition of forkhead box O1 (FoxO1) (151-153). In animal models, 
dietary C3G fed at 0.2% of the diet (w/w) for 5 weeks has been shown to improve insulin 
sensitivity and adipose tissue inflammation in diet-induced obese C57BL/6 mice(18)and 
genetically diabetic mice (18, 154). Purified anthocyanins have also displayed protective effects 
against hepatic steatosis (18) and nonalcoholic steatohepatitis (NASH) (155) in mouse models.In 
human clinical studies, purified anthocyanin supplementation (~300 mg/d) has been shown to 
improve systemic markers of inflammation in healthy (15) and hypercholesterolemic adults 
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(156)compared to placebo. However, humansdo not consume purified anthocyanins in isolation, 
and there is evidence of synergistic effects of different anthocyanins when used in combination 
(156).  Therefore, it is crucial to investigate obesity-protective effects of anthocyanins from 
whole foods, extracts, and asisolated compounds.   
 
Black elderberry (Sambucusnigra) contains one of the highest anthocyanin contents reportedin 
foods (1316 mg/100 g fresh weight)(157).  The major anthocyanins present in black elderberry 
include C3G and cyanidin 3-sambubioside(158, 159). Black elderberry is commonly consumed 
in European cultures in wines and other processed beverages(160), with similar products 
available in the United States.  The berry has been used for centuries in traditional medicine 
throughout European and Native American cultures (160); however, research on its therapeutic 
potential is limited.Therefore, weinvestigated the effects of anthocyanin-rich black elderberry 
extract (BEE) on the metabolic disturbances associated with obesity using the high-fat diet-
induced obese C57BL/6J mouse model.  We hypothesized that BEE feeding would attenuate the 
low-grade inflammation and insulin resistance in this mouse model of obesity. 
 
Materials and methods 
ANIMALS AND DIETS 
TABLE 3.2.1 Study Design 
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High fat diet-fed C57BL/6 mice were used as a diet-induced model of obesity. Male C57BL/6J 
mice (8 weeks of age, n = 56) were obtained from The Jackson Laboratory (Bar Harbor, ME) 
and allowed to acclimate to the animal facility for 2 weeks before being fed 1 of 4 experimental 
diets for 16 weeks:low fat diet control group (LFD; 10% kcal as fat; n = 8);high fat diet control 
group(HFD; 60% kcal as fat; n = 16); high fat diet with 0.25% of BEE added by weight (0.25%-
BEE; 60% kcal as fat; n = 16); and high fat diet with 1.25% of BEE added by weight (1.25%-
BEE; 60% kcal as fat; n = 16). Spray-dried BEE (Sambucusnigra) (standardized to 13% 
anthocyanins) was kindly provided by Artemis International (Fort Wayne, IN.). A single batch of 
BEE was obtained from the supplier. BEE anthocyanins were previously characterized by HPLC 
and shown to be primarily in the form of cyanidin 3-sambubioside and C3G (158). The 0.25%-
BEE and 1.25%-BEE diets corresponded to 0.034% anthocyanin (w/w) and 0.17% anthocyanin 
(w/w) in diets, respectively.Carbohydrate content of diets containing BEE was adjusted to match 
control HFD composition by replacing maltodextrin with BEE. A detailed composition of the 
diets (Supplemental Table 1), vitamin mix (Supplemental Table 2), and mineral mix 
(Supplemental Table 3) is provided in the Online Supporting Material.Food intake and body 
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weight were assessed weekly. Fresh diet was provided to mice twice per week. After 16 weeks 
on experimental diets, mice were fasted for 6-8 hr prior to blood collection by cardiac puncture 
and euthanasia. Blood was allowed to clot at room temperature for 30 minutes before serum was 
isolated by centrifugation (10,000 x g for 10 minutes at 4°C) and then stored at -80°C. Tissues 
were perfused with saline before being harvested, snap-frozen in liquid nitrogen and stored at -
80˚C. Liver and adipose tissues were fixed in 10% neutral-buffered formalin for at least 48 hours 
prior to histological analysis. All mice were housed in a temperature-controlled room and 
maintained in a 12hr light/12 hr dark cycle at the University of Connecticut-Storrs vivarium.The 
Animal Care and Use Committee of the University of Connecticut-Storrs approved all 
procedures used in the current study. 
SERUM BIOCHEMICAL ANALYSIS 
Total cholesterol, non-esterified fatty acids (NEFA), triglycerides, glucose, alanine 
aminotransferase (ALT), and paraoxonase-1 (PON1) activitywere measured using enzymatic 
assays as described (158). Fasting insulin, monocyte chemoattractant protein 1 (MCP-1), 
interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα), adiponectin, resistin, and plasminogen 
activator inhibitor (PAI) were measured by Luminex/xMAP magnetic bead-based multiplexing 
assays using MAGPIX instrumentation (EMD Millipore, Billerica, MA).The Homeostasis Model 
Assessment (HOMA-IR) equation was used to estimate insulin resistance based on fasting serum 
insulin and glucose measurements(161).  
TISSUE LIPID EXTRACTION AND ANALYSIS 
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Hepatic lipids were extracted using methods previously reported (158).  Briefly, the lipids were 
extracted with chloroform: methanol (2:1), dried under nitrogen at 60°C, and solubilized in 
Triton X-100 before being analyzed for cholesterol and triglyceride via enzymatic methods. 
RNA ISOLATION, CDNA SYNTHESIS AND REAL-TIME QRT-PCR 
Total RNA was isolated from liver, skeletal muscle, and adipose tissues using TRIzol reagent 
(Life Technologies, Carlsbad, CA). RNA was then DNase I-treated and reverse transcribed using 
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Gene expression was measured by real-
time qRT-PCR using SYBR Green (Bio-Rad, Hercules, CA) and a CFX96 real-time PCR 
detection system (Bio-Rad, Hercules, CA).A detailed list of all primer sequences used in qRT-
PCR analysis is provided in the Online Supporting Material (Supplemental Table 4).  Liver 
mRNA expression data was normalized to the geometric mean of the reference genes Gapdh and 
36B4.  The geometric mean of Gapdh, 36B4, and β-actin was used as a reference gene control 
for adipose and skeletal muscle mRNA analysis.Expression relative to the reference control 
genes was determined using the 2−∆∆Ct method. 
HISTOLOGICAL ANALYSIS OF TISSUES 
Formalin-fixed liver and epididymaladipose tissue were embedded in paraffin and cut into 5-µm 
sections prior to staining. Liver sections were stained with hematoxylin and eosin (H&E), while 
adipose sections were H&E stained or subjected to Masson’s trichrome staining to visualize 
connective tissue. All histological procedures were conducted at the Connecticut Veterinary 
Medical Diagnostic Laboratory (Storrs, CT, USA). The stained tissue sections were viewed 
under bright field microscopy at ×200magnification and images were taken with AxioCam 
ICc3(Zeiss, Thornwood, NY, USA).The extent of macrophage infiltration into adipose tissue 
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was assessed by the manual counting of crown-like structures (CLS) (3 slides per animal) 
performed by a technician blinded to group assignment.  
STATISTICAL ANALYSIS 
One-way analysis of variance (ANOVA) was used to detect differences between groups with 
post hoc multiple comparisons when appropriate (P< 0.05 deemed significant). GraphPad Prism 
version 6 software was used to conduct all statistical analysis. Data are reported as mean ± SEM.  
Results 
EFFECTS OF BEE ON FOOD INTAKE AND BODY WEIGHT 
While there were no differences in food intake (Fig. 1A) between any of the four groups, the 
HFD groups had greater body weight and weight change after 16 weeks than the LFD group 
(Fig. 1B, C).  There were no differences in body weight or weight change among the HFD 
groups.  Liver weights were ~13%lower in both the 0.25% and 1.25%-BEE groups relative to the 
HFD control group (Fig. 1D). 
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FIGURE 3.3.1 Food Intake, Body Weight, and Liver Weight 
 
Figure 1. BEE reduces liver weight with no change in food intake or weight gain.  Food 
intake (A) and body weight of animals (B) was measured weekly. Mean weight change was 
calculated after 16 weeks (C) and liver weight was measured upon sacrifice (D) (n = 8-16 per 
group, mean ± SEM). Values with different superscripts are P< 0.05.  
 
BEE LOWERS SERUM TRIGLYCERIDES, INFLAMMATORY MARKERS, AND 
INSULIN RESISTANCE 
Serum and liver markers after 16 weeks are presented in Table 1.  Serum triglycerides were 
significantly reducedcompared to HFD control in the 0.25%-BEE and 1.25%-BEE groups by 
25% and 30%, respectively.  There was a significant increase in total serum cholesterol, PON1 
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activity, and ALTin the HFD groups relative to LFD control; however, there were no differences 
within the HFD groups. No differences in serum NEFA were observed between the groups.  The 
HFD control group displayed significant elevations in MCP-1, IL-6, TNFα, resistin, and PAI-1 
as well as a reduction in adiponectin compared to LFD control (Fig. 2A, B). BEE-feeding 
attenuated the HFD-dependent increase in several serum inflammatory cytokines/chemokines. 
There were significant reductions in MCP-1 (-37%) and TNFα (-47%) with the 0.25%-BEE dose 
and a significant reduction in MCP-1 (-30%) with the 1.25%-BEE dose (Fig. 2A). However, 
BEE-feeding did not attenuate the effects of HFD on serum IL-6, resistin, PAI-1, and 
adiponectin (Fig. 2A, B). Fasting serum insulin was 32% lower in the 0.25% BEE group 
compared to HFD control (Fig. 2C) andHOMA-IR, a metric of insulin resistance, was 
significantly lower in both BEE groups compared to HFD control (Fig. 2D).   
 
 
TABLE 3.3.1 and liver markers of C57BL/6J mice after 16 wk 
Variables LFD HFD 0.25%-BEE 1.25%-BEE 
Total Cholesterol, mg/dL 132.67 ± 4.06a 188.59 ± 9.85b 179.61 ± 9.25b 181.00 ± 7.10b 
HDL-Cholesterol, mg/dL 87.34 ± 5.20a 132.10 ± 7.79b 119.89 ± 6.86b 128.97 ± 7.87b 
Triglycerides, mg/dL 32.71 ± 5.0a 48.71 ± 2.98b 36.36 ± 2.83a 33.69 ± 4.84a 
NEFA, mmol/L 0.62 ± 0.05a 0.66 ± 0.03a 0.66 ± 0.03a 0.60 ± 0.04a 
PON1 activity, kU/L 77.88 ± 1.60a 104.98 ± 2.70b 94.04 ± 4.07b 98.37 ± 2.86b 
ALT, IU/L 15.93 ± 2.71a 43.21 ± 3.13b 39.36 ± 3.16b 41.26 ± 4.08b 
Relative Liver Weight, %  4.64 ± 0.32a 6.79 ± 0.23b 6.10 ± 0.23b 6.26 ± 0.32b 
  
 
Each value represents the mean ± SEM of values from n = 8-16 mice per group. Superscripts 
with different letters indicate significant differences at p<0.05. ALT, alanine aminotransferase; 
NEFA, non-esterified fatty acids; PON1, paraoxonase-1. 
54 
 
FIGURE 3.3.2 Serum Inflammatory Markers and Insulin Sensitivity 
 
Figure 2. BEE reduces serum inflammation and insulin resistance.  Serum 
cytokines/chemokines, adipokines, and insulinwere examined by multiplexing assays (A,B, C).  
HOMA-IR was calculated as [(glucose mg/dL)*(insulinmU/L)/405] (D) (n = 8-16 per group, 
mean ± SEM).  Values with different superscripts are P< 0.05. 
BEE REDUCES HEPATIC CHOLESTEROL AND LIPOGENIC GENE EXPRESSION  
HFD feeding significantly increased hepatic lipids compared to LFD control, suggesting the 
development of hepatic steatosis (Fig. 3B, C). This observation was confirmed by examination 
of H&E stained livers, where extensive lipid droplet accumulation was seen in the HFD groups 
(Fig. 3A). Hepatic lipid accumulation with HFD appeared to be slightly attenuated by BEE 
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feeding (Fig. 3C).  However, only hepatic cholesterol in the 1.25%-BEE group was significantly 
lower (-32%) than HFD control, whereas hepatic triglyceride did not differ significantly between 
HFD groups (Fig. 3B, C).  Following hepatic lipid analysis, we performed real-time qRT-PCR 
analysis to assess hepatic mRNA expression of lipid metabolism-related genes.  Expression of 
the lipogenic gene fatty acid synthase (FAS) was significantly reduced in both BEE-fed groups, 
while peroxisome proliferator-activated receptor gamma 2 (PPARγ2) was significantly reduced 
only in the 1.25% BEE group relative to the HFD control (Fig. 4), corresponding with 
histological and biochemical analysis.   
FIGURE 3.3.3 Liver Lipids and Histology 
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Figure 3.Effect of BEE on hepatic lipids and steatosis development.Liver H&E histology was 
performed as described in methods (A) (n = 8per group, mean ± SEM). Hepatic lipids were 
extracted with chloroform: methanol (2:1), dried under nitrogen at 60°C, and solubilized in 
Triton X-100 as described in methods. Cholesterol and triglyceride were measured by enzymatic 
methods (B, C) (n = 8-16 per group, mean ± SEM). Values with different superscripts are P< 
0.05. 
FIGURE 3.3.4Liver mRNA Expression 
 
Figure 4. BEE reduces lipogenic mRNA expression in the liver.  Hepatic mRNA expression 
was measured by real-time qRT-PCR.  Data was normalized to endogenous reference gene 
expression (A) (n = 8-16 per group, mean ± SEM). Values with different superscripts are P< 
0.05.  
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BEE DOES NOT ATTENUATE ADIPOSE TISSUE MACROPHAGE INFILTRATION 
AND FIBROSIS 
Compared to the LFD group, all HFD groups had a noticeable increase in macrophage 
infiltration indicated by H&E staining, with an increased number of crown like structures (CLS) 
(Fig. 5A,B). There were no differences in CLS among the HFD groups as all groups appeared to 
have extensive immune cell infiltrationand large pockets without adipocytes, suggesting fibrosis. 
The adipose tissue became markedly fibrotic in the HFD groups, as shown by Masson’s 
trichrome blue staining of connective tissue (Fig. 5C).Indeed, the large pockets that lacked 
adipocytes stained strongly for connective tissue, and this staining appeared to be greatest in the 
1.25%-BEE group relative to the other HFD groups.  To further examine adipose tissue, real-
time qRT-PCR was performed to examine changes in mRNA expression between HFD groups 
(Fig. 5D).  In the 1.25%-BEE group, there were significant increases in expression of PPARγ 
and a PPARγ target gene, adipocyte protein 2 (aP2), compared to the HFD control group.  
Another PPARγ target gene, lipoprotein lipase (LPL), was significantly higher in the 1.25%-BEE 
group relative to 0.25%-BEE group. F4/80, a macrophage marker, was also more highly 
expressed in the 1.25%-BEE group compared to HFD control and 0.25%-BEE groups.  
Interestingly, although the 1.25%-BEE group had greater F4/80 mRNA expression, TNFα 
expression was significantly reduced compared to the 0.25%-BEE group, suggesting that the 
macrophages were less inflammatory. The expression of CD11c, a phenotypic marker of 
“classically activated” M1-like inflammatory macrophages, was not different between any of the 
groups suggesting that 1.25%-BEE macrophages are of the M2-like “alternatively activated” 
phenotype that remodel adipose tissue and are not inflammatory. Supporting this notion, mRNA 
expression of TGFβ,a pro-fibrogenic cytokine, was increased in the 1.25%-BEE group relative to 
 the other HFD groups. Additionally, 
that is highly-enriched in adipose, was 
to the 0.25%-BEE group.  
FIGURE 3.3.5 Epididymal Adipose Histology, CLS, And mRNA
Figure 5.Effect of BEE on adipose tissue inflammation and fibrosis.
(A) and Masson’s trichrome (C)staining 
structures (CLS) were manually counted from adipose H&E 
200X high-powered fields (HPF)
expression was measured by real
gene expression (D) (n = 16 per group, mean ± SEM). 
0.05. 
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collagen VI alpha 3 (Col6a3), a downstream target of TGF
significantly increased in the 1.25%-BEE group relative 
 Expression
Epididymal adipose H&E 
was performed as described in methods. 
stains and averaged across 3 random 
(B) (n = 8 per group, mean ± SEM).  Adipose mRNA 
-time qRT-PCR.  Data was normalized to endogenous reference 
Values with different superscripts are 
β 
 
 
Crown-like 
P< 
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BEE ALTERS LIPID METABOLISM-RELATED GENE EXPRESSION BUT DOES 
NOT ATTENUATESKELETAL MUSCLE INFLAMMATION 
To examine skeletal muscle inflammation and metabolic function, mRNA expression in 
quadriceps was measured (Fig. 6). Compared to LFD control, high fat diet feeding resulted in 
higher mRNA expression ofskeletal muscle MCP1 and the macrophage marker, CD68, 
suggesting the obese state caused inflammation in this tissue. BEE-feeding was unable to alter 
MCP1 or CD68 expression compared to HFD control. There was also a marked increase in the 
expression of lipid metabolism-related genes, ACAD, LPL, and acyl-CoA oxidase (ACOX) with 
high fat feeding compared to LFD. LPL andACOX expression were decreased significantly in 
the 1.25% BEE group relative to the HFD control. Interleukin-6 (IL-6), a myokine and regulator 
of substrate utilization, was increased by 2.7-fold in the 0.25% BEE group compared the HFD 
control group.   
FIGURE 3.3.6Skeletal Muscle mRNA Expression 
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Figure 6.Effect of BEE on skeletal muscle gene expression.Skeletal muscle mRNA was 
measured by real-time qRT-PCR.  Data was normalized to endogenous reference gene expression 
(A) (n = 8-16 per group, mean ± SEM). Values with different superscripts are P< 0.05. 
Discussion 
Targeting the excessive lipid accumulation and inflammation in obesity may lead to successful 
therapies that reduce the prevalence of obesity-related comorbidities(148).  Anthocyanins are 
dietary bioactives that have been shown to reduce inflammation and insulin resistance in obese 
animals (18, 154). Black elderberry is a berry rich in anthocyanins but there is limited research 
examining its effects on inflammation in chronic disease models. In this study, C57BL/6J mice 
fed BEE were shown to have an attenuation of insulin resistance and systemic inflammation 
compared to HFD controls. BEE-fed mice were also shown to have lower serum triglycerides 
and modest reductions in hepatic lipids compared to HFD controls. These changes suggest that 
BEE may have potential in ameliorating the lipotoxicity and inflammation present in obesity.  
Anthocyanins have been shown to have limited bioavailability and are not found in the 
serum in significant quantities (less than 1%) upon feeding (162).  Because of this, some have 
questioned how the consumption of anthocyanin-rich foods may be eliciting their effects (163).  
Recently, Czank et al. (72)showed that ingestion of 500 mg 13C-isotopically labeled C3G by 
humans was ~12% bioavailable (excreted via urine and breath) in the form of metabolites. C3G 
is degraded to protocatechuic acid (PCA), either spontaneously or after catabolism by the gut 
microbiota, which can then be absorbed and enter the bloodstream(21). Compared to intact C3G, 
much higher concentrations of these phenolic degradation products and their phase II conjugates 
were found in serum, urine, and feces in human subjects after 13C-labeled C3G ingestion (23). In 
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this case, it is likely that the metabolites of anthocyanins are primarily responsible for their 
physiological effects.   
In the current study, both groups of BEE-fed mice were found to have improvements in 
many serum markers of obesity-related metabolic complications. BEE-fed mice had 25-30% 
reductions in fasting serum triglycerides compared to HFD control, although no other significant 
differences were observed in serum lipids. BEE appeared to attenuate systemic inflammation, as 
mice fed the lower dosage of BEE had >30% lower serum MCP1 and TNFα, whereas only 
MCP1 reached significance in the higher dosage group. Both BEE-fed groups displayed 20% and 
40% reductions in fasting insulin and HOMA-IR, respectively, which suggests that BEE reduced 
insulin resistance in these obese mice.   
BEE-fed mice also displayed modest changes in markers of hepatic steatosis that increase 
with diet-induced obesity. BEE-fed mice were found to have 13% lower liver weights compared 
to HFD control. There appeared to be a modest attenuation of hepatic steatosis in the 1.25%-BEE 
group compared to the HFD control, with noticeably smaller lipid droplets, suggesting less 
macrosteatosis. A significant reduction of hepatic cholesterol by 32% and a non-significant 16% 
attenuation in hepatic triglyceride in the 1.25%-BEE group confirm this observation. These 
changes may be explained in part by reductions in hepatic FAS and PPARγ2 mRNA in the 
1.25%-BEE group. No changes in β-oxidation-related gene expression were observed among the 
HFD groups, suggesting BEE influenced triglyceride synthesis rather than oxidation.  
The effects of BEE-feeding on adipose tissue did not appear to explain the differences in 
serum markers between HFD groups. Despite no changes in the epididymal adipose CLS count 
among the HFD groups, the 1.25%-BEE displayed a 211% increase in the mRNA expression of 
the pan-macrophage marker, F4/80.  Although F4/80 expression was increased, the 1.25%-BEE 
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group adipose tissue did not appear inflamed, having significantly lower TNFα expression than 
the 0.25%-BEE group and this approached significance compared to HFD control. Furthermore, 
CD11c, a marker of pro-inflammatory “classically activated” M1-like macrophages, was not 
increased in the 1.25%-BEE group. Adipose mRNA expression of PPARγ and TGFβ, which are 
induced in M2-like “alternatively activated” macrophages (42, 164), was significantly increased 
in the 1.25%-BEE groups compared to HFD control. Potentially, the macrophages in the 1.25%-
BEE adipose tissue were more of an M2-like phenotype, where they would be pro-resolving and 
anti-inflammatory. Expression of PPARγ target genes (aP2, LPL) were increased in 1.25%-BEE 
adipose relative to other HFD groups, suggesting that PPARγ activity was increased. PPARγ 
activation in macrophages has been shown to induce an anti-inflammatory M2-like phenotype 
that improves metabolic function in obese mice (164, 165). Alternatively activated M2-like 
macrophages have also been shown to stimulate fibrogenesisvia production of TGFβ (166). 
Connective tissue staining of sectioned adipose tissue appeared to be somewhat greater in the 
1.25%-BEE group, which also displayed a higher expression of Col6a3, a fibrogenic gene 
induced downstream of TGFβ signaling (167). In human obese subjects, adipose tissue 
macrophages that were present in fibrotic areas and not in CLS were shown to be primarily M2-
like macrophages, which produce TGFβ and increase adipocyte collagen VI (42). Thus, despite 
the strong induction of F4/80 mRNA in the 1.25%-BEE adipose, the infiltrated macrophages do 
not appear to be inflammatory and may be of the M2-like anti-inflammatory and pro-fibrogenic 
phenotype.  
Skeletal muscle mRNA expression of LPL and AOX were reduced by 50% and 46% in 
the 1.25%-BEE group compared to HFD control, which indicates major changes in fatty acid 
metabolism.  However, these genes were highly induced in all HFD groups compared to LFD, 
63 
 
suggesting that these decreases with the 1.25%-BEE dose were indicative of an attenuation of the 
HFD effect. This may possibly be explained by reduced fatty acid availability to the skeletal 
muscle as a consequence of greater adipose PPARγ activation and adipose fatty acid buffering 
capacity. With long-term HFD feeding in mice (>12 weeks), skeletal muscle can exhibit 
extensive macrophage infiltration and inflammation similar to adipose tissue (168). BEE-feeding 
was unable to attenuate the apparent macrophage infiltration (>30-fold increases in CD68 mRNA 
expression) and inflammation with HFD feeding (>5-fold increases in MCP1 mRNA 
expression). Of interest was the 2.7-fold increase in IL-6 mRNA expression in the 0.25%-BEE 
group compared to HFD control. IL-6 is a myokine and somewhat controversialin regardsto its 
effects in skeletal muscle, systemic glucose tolerance, and insulin resistance (169, 170). 
Although traditionally viewed as an inflammatory cytokine that increases hepatic insulin 
resistance, increasing evidence points to a beneficial metabolic role in promoting glucose uptake 
and fatty acid oxidation in skeletal muscle (171, 172). This may be significant in regulating 
systemic glucose tolerance since the skeletal muscle is the major organ involved in whole-body 
glucose disposal (173). 
Our findings are consistent with other reports that have fed anthocyanins and 
anthocyanin-rich foods to obese rodent models (Table 3.4.1). Guo et al. (18)observed significant 
reductions in plasma insulin, HOMA-IR, MCP-1, and TNFα, with no changes in IL-6 after 5 
weeks of 0.2% (w/w) C3G feeding diet-induced obese C57BL/6 mice. We also reported 
reductions in fasting insulin and HOMA-IR by 20-30% and 40%, respectively. DeFuria et al. 
(174) also observed decreases in insulin resistance in C57BL/6J mice fed blueberry powder in 
the diet at 4% by weight (~0.12% anthocyanins) for 8 weeks. Similarly, Chuang et al. (175) 
reported an improvement in glucose tolerance in diet-induced obese C57BL/6 mice fed 3% 
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(w/w) grape powder for 18 weeks. The significant reductions in serum MCP-1 (37% and 30% in 
0.25%-BEE and 1.25%-BEE groups respectively, relative to HFD control) and TNFα (47% in 
the 0.25%-BEE group relative to HFD control), are comparable to the 25% reduction in serum 
TNFα observed by Vendrame et al. (176) in obese Zucker rats fed blueberry powder at 1.5% of 
the diet for 8 weeks. Chuang et al. (175) similarly reported 30-50% reductions in serum 
inflammatory markers, including TNFα and MCP-1, in grape powder-fed diet-induced obese 
mice. Therefore, the results we report in this study are consistent with previous findings on the 
efficacy of anthocyanin-rich foods in ameliorating inflammation and insulin resistance in obese 
rodent models. 
 
TABLE 3.4.1 Related Obesity Findings with Anthocyanin Feeding 
Author 
(Year) 
Berry Objective Design Findings 
Vendrame 
et al. 
(2013)(176) 
Wild blueberry 
(Vacciniumangustifolium) 
Blueberry on 
inflammation 
status in 
obese Zucker 
rats 
Freeze-dried wild 
blueberry powder 
(WB) at 1.5% or 
CTL fed for 8 weeks.  
Serum collected and 
RNA isolated from 
liver and adipose 
25.6% 14.9%, and 
13.1% lower serum 
TNFα, IL6, and C-
reactive protein 
(CRP) respectively 
in WB fed mice.  
TNFα, IL6, and 
NF-kB mRNA 
expressions were 
59%, 65%, and 
25% lower 
respectively in the 
liver and 52%, 
64%, and 65% 
lower in the 
abdominal adipose. 
DeFuria et 
al.  
(2009)(174) 
Whole blueberry Blueberry on 
adipose 
inflammation 
and insulin 
resistance in 
C57BL/6J 
Freeze-dried whole 
blueberry powder 
(BB) at 4% or CTL 
fed for 8 weeks. 
Serum collected for 
analysis.  Epididymal 
Reductions in 
adipocyte death, 
insulin resistance 
and hyperglycemia 
in BB fed mice.  
CD11c/MGL1 
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mice adipose (EA) 
collected for 
histology and RNA 
isolation. 
mRNA expression 
ratio significantly 
lower in BB fed 
mice.  TNFα and 
IL10 EA mRNA 
expression 
significantly lower 
in BB fed mice, 
while glutathione 
peroxidase 3 
(GPx3) mRNA 
expression was 
higher in BB fed 
mice. 
Lee et al. 
(2014)(177) 
Blueberry leaf extract Blueberry leaf 
extract (BLE) 
on weight 
gain and 
adipogenesis 
in C57BL/6J 
mice 
C57BL/6J mice fed 
HFD to induce 
obesity for 4 weeks 
then they were fed 
either LFD (N mice), 
HFD (C mice), HFD 
plus 5% catechin in 
drinking water (PC 
mice) or HFD plus 
2% BLE in drinking 
water ab libitum for 4 
weeks 
BLE fed mice 
gained 50% less 
weight than the C 
mice, with 
unchanging food 
intake. BLE fed 
mice had 49% and 
26% lower TG and 
TPC respectively 
than the C mice.  
Liver TBARS 
more than 50% 
lower in BLE mice 
compared to C 
mice.  BLE 
demonstrated less 
adipocyte 
differentiation than 
C mice with small 
fat cells and lower 
PPAR-γ expression 
in the white 
adipose tissue.  
BLE also had 
improved glucose 
control with 42% 
and 25% lower 
insulin and glucose 
respectively than C 
mice. 
Charradi et 
al. 
Grapes Grape powder 
polyphenols 
Wistar rats 
administered vehicle 
GPP rats had 
significantly higher 
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(2014)(178) or grape powder 
polyphenols (GPP) 
solubilized in 10% 
ethanol and 
administered by 
intraperitoneal 
injection at 500mg/kg 
for 6 weeks 
glutathione 
peroxidase, 
superoxide 
dismutase, and 
significantly lower 
liver triglyceride, 
lipid and protein 
oxidation than the 
HFD CTL rats 
Chuang et 
al. 
(2012)(175) 
Grapes Grape powder 
(GP) and 
grape powder 
extract (GE) 
on mice 
C57BL/6J mice on 
HFD were fed HFD, 
HFD plus 3% GP or 
HFD plus 0.02% GE 
for 18 weeks and 
inflammatory 
markers were 
measured  
GP fed mice had 
30-50% reductions 
in serum 
inflammatory 
markers (such as 
TNFαand MCP1) 
and improved 
glucose tolerance 
acutely assessed by 
glucose tolerance 
test (GTT) 
     
 
In conclusion, BEE-fed mice had reduced serum inflammatory markers and insulin 
resistance, as measured by HOMA-IR. BEE-fed mice had lower fasting triglycerides and modest 
reductions in hepatic lipids, possibly explained by reductions in hepatic FAS and PPARγ2. 
Despite a lack of difference in CLS in the HFD groups, the 1.25%-BEE-fed mice appeared to 
have more macrophage infiltration in the adipose tissue, as demonstrated by greater F4/80 
mRNA expression. These macrophages do not appear to be inflammatory, however, and may be 
depositing more collagen. Across the tissues, changes in mRNA expression in the BEE-fed 
groups suggest differences in fatty acid metabolism including potentially decreased lipogenesis 
in the liver and increased adipogenesis in the adipose tissue. Both BEE doses appear to attenuate 
some of the complications induced by HFD feeding, although the 1.25% (w/w) dose does not 
appear to improve upon the serum changes observed with the 0.25% (w/w) dose and may even 
cause complications in the adipose due to fibrogenic effects. Overall, BEE appeared to attenuate 
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systemic inflammation and insulin resistance that occurs with diet-induced obesity in this mouse 
model, but further research is warranted on black elderberry consumption and effects in humans.   
 
Summary and Conclusions 
 In this thesis, a good deal of data is presented regarding the application of BEE to prevent 
CVD and metabolic dysfunction in obesity and while the data is very interesting,it is not yet 
entirely clear how beneficial black elderberry is for these conditions.  At least several more 
studies will need to be conducted before any confident statements can be made on the topic.  
There are, however, some things that can be said from the studies discussed above.   
From the first aim, in which BEE was investigated for its effects on improving HDL 
function and reducing atherosclerosis as measured by aortic cholesterol, there is some reason to 
believe that BEE-feeding was successful.  BEE raised PON1 activity, lowered blood markers of 
inflammation such as MCP1, improved HDL function related proteins and genes, and lowered 
aortic cholesterol.  Although surprising that BEE did not affect blood lipids, the majority of our 
hypothesis for this aim was met. 
For the second aim investigating the effect of BEE on obesity related inflammation and 
metabolic dysfunction our results are quite curious.  Most notably we observed reduced serum 
triglycerides possibly explained by reductions in FAS and other lipogenic genes in the liver, 
lower serum inflammatory markers such as MCP-1 and TNFα, and reduced insulin resistance in 
BEE-fed mice.  However, some of our findings were interesting.  The 0.25% group had modestly 
lower serum MCP-1, TNFα, and insulin than did the 1.25% BEE group, creating what was 
initially interpreted as informationpointing towards an optimal dose.  On the other hand, this was 
complicated when it was found thatlipogenic gene expression was lower in the liver and 
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protective PPARγ genes were higher in the adipose in the 1.25% BEE group compared to the 
0.25% group.  To make things even more complicated, macrophage infiltration and fibrogenesis 
were higher in the 1.25% BEE group than in the 0.25 BEE group.  It is not clear whether this 
increase in fibrogenesis in the 1.25% group is the result of increased tissue damage or a less 
inflammatory, more reparative phenotype. It is also not clear what a safe dose is.  The CVD 
study did not investigate the effects of varying doses, however, the obesity did and so the data 
from this latter study may be consulted to help determine in which direction the optimal dose 
may lie.   Although ALT and AST readings indicate that neither dose seems to be toxic to the 
liver, we present some evidence here (such as the collagen deposition related histology and data) 
suggesting that a 0.25% dose of BEE may be safer than a 1.25% dose.  We present some data 
that we have interpreted as a positive effect of the BEE, however, we also present data that we 
did not expect.  It is too early to generalize findings outside of the model and design of these 
studies. 
 In conclusion, we found that BEE improved HDL function associated with 
chronic inflammation in ApoE-/- mice and lowered serum triglycerides, inflammatory markers, 
and insulin resistance in diet-induced obese C57BL/6J mice. Although there were some 
surprising findings, our hypotheses were, for the most part, met.  These results suggest that BEE 
may serve as a useful dietary component to ameliorate some of the complications that occur in 
CVD and obesity, however, use as a dietary aid cannot yet be recommended.  Further research is 
warranted.   
 
Future Directions 
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 Future research on BEE in CVD should investigate different dosages for a longer period 
of time ApoE-/- will be fed anAIN-93M diet supplemented with 0.25% (wt/wt) or 1.25 (wt/wt) 
BEE or control diet for 20 weeks.  Some mice from each group will be given antibiotics to test 
the influence of the gut microbiota on the effects of BEE.  For the metabolic dysfunction in 
obesity aim, we observed complicated trends in our data, especially concerning the adipose 
tissue.  Future research may include conducting a similar study to confirm our preliminary 
findings or perhapssome cell culture studies to explore mechanisms that may explain these 
trends.  Human trials in which BEE supplements are given to subjects to take daily are also of 
interest.  Blood would be drawn periodically to measure blood lipids, inflammatory markers, 
HDL function related proteins, PON1 activity, etc.  However, formal plans for such studies have 
not been made. 
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